Open clinical trials in mainland China
1,699 open trials registered on ClinicalTrials.gov with at least one of 308 hospitals on this site as lead sponsor or study site, as registered on 8 Nov 2026. Filter by disease, city, phase and the registered age and sex.
Not a ranking or a recommendation. Whether someone can take part is decided by the study team. Trials registered only in China’s own registry (ChiCTR) are not included.
- RecruitingA Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT05199688
Age 2 years to 11 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingEnvafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT06059261
Age 18 years to 65 years (registered criteria)
Led by Chongqing University Cancer HospitalChongqing
- RecruitingSafety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT06326008
Age 1 year to 18 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingTP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Registry
- NCT06726577
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou
- RecruitingEfficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
- Phase
- N/A
- Started
- 2026-01
- Registry
- NCT06794073
Age 18 years to 80 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingHypofractionated Radiotherapy for Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2026-02
- Registry
- NCT06796270
Age 18 years to 75 years (registered criteria)
Led by Hainan General Hospital / Hainan Medical University hospitalsHaikou
- RecruitingInternational Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer
- Phase
- Not given
- Started
- 2026-01
- Registry
- NCT07013461
Age 18 years to Not stated (registered criteria)
Led by The University of Hong Kong–Shenzhen HospitalShenzhen
- RecruitingDaoyin Technique for Improving Exercise Endurance in IPF
- Phase
- N/A
- Started
- 2026-04
- Registry
- NCT07019714
Age 40 years to 85 years (registered criteria)
Led by Affiliated Hospital of Liaoning University of Traditional Chinese Medicine; 2 listed hospitals as study sitesBeijing, Shenyang, Zhengzhou
- RecruitingThe Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07039474
Age 18 years to 75 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingStudy to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07061938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Chengdu, Shanghai, Wuhan
- RecruitingA Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07070076
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Jinan UniversityGuangzhou
- RecruitingA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Phase
- Phase 2/Phase 3
- Started
- 2026-03
- Registry
- NCT07221149
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Nanning, Shanghai
- RecruitingA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07221669
Age 0 days to 42 days (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou
- RecruitingPD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07235319
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 4 listed hospitals as study sitesChangsha, Fuzhou, Guangzhou, Hangzhou, Nanning
- RecruitingSingle-port Robotic Radical Gastrectomy for Gastric Cancer
- Phase
- N/A
- Started
- 2026-07
- Registry
- NCT07237126
Age 18 years to 75 years (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- RecruitingNeoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07244978
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingStratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
- Phase
- Phase 3
- Started
- 2026-03
- Registry
- NCT07246330
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingKSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2026-01
- Registry
- NCT07246707
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07249632
Age 12 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT07255898
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- RecruitingA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-02
- Registry
- NCT07258511
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanjing, Nanning, Wenzhou, Wuhan, Xi'an
- RecruitingNIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
- Phase
- Early phase 1
- Started
- 2026-01
- Registry
- NCT07295262
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingSafety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07295275
Age 18 years to 80 years (registered criteria)
Led by West China Hospital; 2 listed hospitals as study sitesBeijing, Chengdu, Xuzhou
- RecruitingDiagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
- Phase
- Not given
- Started
- 2026-01
- Registry
- NCT07295340
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingPhase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07310173
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- RecruitingSHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07311408
Age 18 years to Not stated (registered criteria)
Led by Liaoning Cancer Hospital & InstituteShenyang
- RecruitingA Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07315750
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPhase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07318831
Age 0 years to 18 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingIASO206 in Patients With Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2026-01
- Registry
- NCT07322159
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingSintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07324824
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingLDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07325539
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Shenzhen
- RecruitingA Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07328009
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingMRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07331428
Age 18 years to 70 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingPD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07332247
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingFirst in Human Study of SIM0610 in Solid Tumors
- Phase
- Phase 1
- Started
- 2026-01
- Registry
- NCT07348211
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang
- RecruitingRemimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy
- Phase
- N/A
- Started
- 2026-01
- Registry
- NCT07351474
Age 65 years to 100 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-01
- Registry
- NCT07351669
Age 18 years to 75 years (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- RecruitingA First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07354711
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study of SHR-2173 in Participants With Primary IgA Nephropathy
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07354932
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingLM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07362186
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingToripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07362979
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesDongguan, Guangzhou, Shenzhen, Zhanjiang
- RecruitingA Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Registry
- NCT07375758
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingIMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features
- Phase
- Not given
- Started
- 2026-01
- Registry
- NCT07376603
Age 18 years to 70 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingEfficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Registry
- NCT07379047
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou
- RecruitingThe Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07381634
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- RecruitingSBRT Versus Surgical Resection for Small HCC
- Phase
- Phase 3
- Started
- 2026-03
- Registry
- NCT07381660
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07385001
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingA Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07387549
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou
- RecruitingPhase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07390123
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changchun, Changsha, Huangshan City, Linyi, Shanghai, Wuhu, Xi'an, Zhanjiang
- RecruitingA Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07392320
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Registry
- NCT07392892
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Wuhan
- RecruitingRomiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07400341
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingDeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective)
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07401173
Age 18 years to 85 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingMultimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
- Phase
- Not given
- Started
- 2026-02
- Registry
- NCT07401199
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShijiazhuang, Wuhan
- RecruitingFull-time RDI for ESD: Impact on Major Adverse Events and Procedure Time
- Phase
- N/A
- Started
- 2026-03
- Registry
- NCT07401303
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingBecotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07403136
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSafety of Robotic Surgery for GISTs at Special Anatomic Sites
- Phase
- N/A
- Started
- 2026-02
- Registry
- NCT07405125
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07405151
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Jinan, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- Phase
- Phase 1
- Started
- 2026-02
- Registry
- NCT07409246
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Tianjin
- RecruitingMRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07409454
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingTherapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
- Phase
- Phase 4
- Started
- 2026-02
- Registry
- NCT07410039
Age 18 years to 65 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingSurgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07410715
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingTislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07413354
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingEfficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
- Phase
- N/A
- Started
- 2026-03
- Registry
- NCT07413835
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou
- RecruitingA Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07416526
Age 12 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07416604
Age 12 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Tianjin
- RecruitingAdjuvant TACE in HCC With High-risk Recurrence Factors
- Phase
- Phase 3
- Started
- 2026-02
- Registry
- NCT07417397
Age 18 years to 70 years (registered criteria)
Led by Guangxi Medical University Cancer HospitalNanning
- RecruitingModified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07420296
Age 18 years to 80 years (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- RecruitingA Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07422753
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingClinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
- Phase
- Early phase 1
- Started
- 2026-02
- Registry
- NCT07429461
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
- Phase
- Early phase 1
- Started
- 2026-03
- Registry
- NCT07429721
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingDigital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy
- Phase
- N/A
- Started
- 2026-03
- Registry
- NCT07441850
Age 18 years to 70 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07444476
Age 15 years to 60 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingBiochemical Response and Clinical Outcomes in Patients With PBC
- Phase
- Not given
- Started
- 2026-02
- Registry
- NCT07449793
Age 18 years to 85 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-03
- Registry
- NCT07452198
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingTime-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07452601
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingTo Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Registry
- NCT07454187
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Suzhou, Xi'an, Zhengzhou
- RecruitingEfficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07457528
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingBecotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
- Phase
- Phase 3
- Started
- 2026-03
- Registry
- NCT07459296
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Guangxi Medical UniversityNanning
- RecruitingAdverse Effects of ATG/ALG Therapy in Aplastic Anemia
- Phase
- Not given
- Started
- 2026-02
- Registry
- NCT07461116
Age not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingPULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07463248
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingQLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07463573
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingSHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07464756
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingTrientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07465718
Age 8 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou
- RecruitingA Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
- Phase
- Early phase 1
- Started
- 2026-04
- Registry
- NCT07470073
Age 12 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingClinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
- Phase
- N/A
- Started
- 2026-03
- Registry
- NCT07470151
Age 18 years to 70 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingDisitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07474324
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07475026
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07477587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2026-04
- Registry
- NCT07478302
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesFuzhou, Nanning
- RecruitingMRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Registry
- NCT07479485
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Tianjin, Zhengzhou
- RecruitingApatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07479732
Age 12 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Registry
- NCT07482059
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingConversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07483359
Age 18 years to 80 years (registered criteria)
Led by First Hospital of China Medical UniversityShenyang
- RecruitingIBI343 in Combination Therapy for Advanced Malignant Solid Tumors
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07483554
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingTACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07487662
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
- Phase
- Phase 2/Phase 3
- Started
- 2026-03
- Registry
- NCT07490262
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase I Study of SHR-3836 in Patients With Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-06
- Registry
- NCT07490613
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou
- RecruitingA Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07492615
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAn Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT07493044
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2026-04
- Registry
- NCT07493135
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingIntelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07495735
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- RecruitingBecotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07496190
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study of YKST02 in Participants With Primary IgA Nephropathy
- Phase
- Early phase 1
- Started
- 2026-05
- Registry
- NCT07498673
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingDual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07500220
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingEfficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07501351
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingDual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07502287
Age 12 months to 21 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingLarge Language Models Assist in Tumor MDT
- Phase
- N/A
- Started
- 2026-01
- Registry
- NCT07504367
Age 25 years to 33 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingCamrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07505186
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAllogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
- Phase
- Early phase 1
- Started
- 2026-04
- Registry
- NCT07507201
Age 3 years to Not stated (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- RecruitingPredicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study
- Phase
- Not given
- Started
- 2026-01
- Registry
- NCT07514052
Age 18 years to Not stated (registered criteria)
Led by Shanxi Bethune HospitalTaiyuan
- RecruitingDynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07517107
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07518147
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07518186
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an
- RecruitingIntensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07519486
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07521852
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesFuzhou, Shanghai
- RecruitingClinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07522151
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07523529
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingAdaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07523555
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingCombination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Registry
- NCT07525466
Age 18 years to Not stated (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingAI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer
- Phase
- Not given
- Started
- 2026-04
- Registry
- NCT07525765
Age 18 years to 90 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingSafety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
- Phase
- Phase 1
- Started
- 2026-04
- Registry
- NCT07526493
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingMaintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07528183
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesFuzhou, Guangzhou, Nanning, Wuhan
- RecruitingStudy to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT07529782
Age Not stated to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Suzhou, Tianjin
- RecruitingBecotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07536789
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingSafety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07537348
Age 18 years to 70 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingSafety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07537361
Age 18 years to 70 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingAI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-04
- Registry
- NCT07538882
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingSafety of KN057 Prophylaxis in Patients With Haemophilia A or B
- Phase
- Phase 3
- Started
- 2026-03
- Registry
- NCT07545395
Age 12 years to 65 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingA Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Registry
- NCT07547553
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Zhengzhou
- RecruitingDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07551362
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingAI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging
- Phase
- Not given
- Started
- 2026-05
- Registry
- NCT07551466
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingOral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07552402
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Chengdu, Dalian, Fuzhou, Hangzhou, Nanning, Shanghai, Shijiazhuang, Suzhou, Wuhan, Yinchuan
- RecruitingA Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
- Phase
- Phase 2/Phase 3
- Started
- 2026-06
- Registry
- NCT07554456
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
- Phase
- Phase 1/Phase 2
- Started
- 2026-07
- Registry
- NCT07554924
Age Not stated to 180 days (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Shanghai
- RecruitingCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07555938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingLM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07556640
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Recruiting18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- Phase
- N/A
- Started
- 2026-04
- Registry
- NCT07557225
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingA Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07557446
Age 12 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Shanghai, Shenzhen, Suzhou
- RecruitingInduction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07559045
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Zunyi Medical UniversityZunyi
- RecruitingTopical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma:
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07559877
Age 18 years to 75 years (registered criteria)
Led by Jiangxi Cancer HospitalNanchang
- RecruitingIpilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07560488
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingTaurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07567742
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTargeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07575919
Age 18 years to 85 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingExploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07575971
Age 18 years to 85 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07579234
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingA Novel Two-Tooth Clip for ESD and EFTR of GIST
- Phase
- N/A
- Started
- 2026-04
- Registry
- NCT07581977
Age 18 years to 85 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07582133
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPhase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07584499
Age 2 years to 18 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingCM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07585760
Age 18 years to 80 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingCD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
- Phase
- Early phase 1
- Started
- 2026-05
- Registry
- NCT07586267
Age 3 years to Not stated (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- RecruitingA Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA
- Phase
- Not given
- Started
- 2026-06
- Registry
- NCT07586735
Age 40 years to 60 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Registry
- NCT07589244
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Recruiting68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Registry
- NCT07590336
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingHAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07594340
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingAdebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07595770
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingEvaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07600125
Age 18 years to Not stated (registered criteria)
Led by Xijing Hospital; 3 listed hospitals as study sitesDalian, Qingdao, Wuxi, Xi'an
- RecruitingEfficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
- Phase
- Phase 4
- Started
- 2026-06
- Registry
- NCT07604311
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingEvaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07614477
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin
- RecruitingLaparoscopic-endoscopic Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric Cancer
- Phase
- N/A
- Started
- 2026-05
- Registry
- NCT07615374
Age not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingPhase I Study of FXS0683 in the Treatment of Blood Tumors
- Phase
- Phase 1
- Started
- 2026-06
- Registry
- NCT07616089
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingSafety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
- Phase
- Phase 1
- Started
- 2026-09
- Registry
- NCT07620275
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General Hospital; 2 listed hospitals as study sitesBeijing, Tianjin
- RecruitingHIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07621484
Age 18 years to 75 years (registered criteria)
Led by Changzheng HospitalShanghai
- RecruitingA Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07622342
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Shanghai
- RecruitingA Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07623798
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingIntratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT07625423
Age 18 years to 65 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingEfficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)
- Phase
- N/A
- Started
- 2026-05
- Registry
- NCT07627347
Age 18 years to 70 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingSurgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07629817
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingPeripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07629947
Age 18 years to 40 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingComparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer
- Phase
- N/A
- Started
- 2026-05
- Registry
- NCT07635836
Age 18 years to 75 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingA Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07638683
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingLenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07639138
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingTwo-component Radiology-guided Autonomous Cascade Engine (TRACE)
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07651644
Age not stated (registered criteria)
Led by Liaoning Cancer Hospital & InstituteShenyang
- RecruitingA Clinical Study of SHR-5421 in Patients With Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07652281
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingCM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07652905
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingTACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07658833
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingGPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
- Phase
- Phase 1
- Started
- 2026-06
- Registry
- NCT07660939
Age 18 years to 80 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingIndividualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2026-07
- Registry
- NCT07661771
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChangsha, Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan
- RecruitingIsatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- Phase
- Not given
- Started
- 2026-06
- Registry
- NCT07663253
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
- Phase
- Phase 3
- Started
- 2026-07
- Registry
- NCT07673887
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingGPC3-Targeted PET/CT in Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2026-05
- Registry
- NCT07677774
Age 18 years to 90 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingStudy Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07687459
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou
- RecruitingChemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07689851
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenzhen, Taiyuan
- RecruitingPD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07697859
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07700667
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Shiyan, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingPhase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07700979
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingEfficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2026-07
- Registry
- NCT07705243
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingEfficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2026-07
- Registry
- NCT07706985
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
- Phase
- Early phase 1
- Started
- 2026-06
- Registry
- NCT07707531
Age 18 years to Not stated (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingClinical Study on Using Laparoscopic Sentinel Lymph Node Navigation Combined With Dual Endoscopy Surgery for Early Gastric Cancer
- Phase
- N/A
- Started
- 2026-01
- Registry
- NCT07708012
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- RecruitingPhase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Registry
- NCT07714512
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingTEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
- Phase
- N/A
- Started
- 2026-07
- Registry
- NCT07714980
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Qingdao University; 5 listed hospitals as study sitesBeijing, Qingdao, Weifang, Weihai, Yantai
- RecruitingComparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07733830
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Shenyang, Taiyuan, Tianjin, Zhengzhou
- RecruitingRetrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset
- Phase
- Not given
- Started
- 2026-05
- Registry
- NCT07747688
Age 18 years to 90 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingA Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07751341
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Zhengzhou
- Recruiting68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07760012
Age 18 years to Not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingA Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Registry
- NCT07760454
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Suzhou
- RecruitingA Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07762872
Age 18 years to Not stated (registered criteria)
Led by Xuanwu HospitalBeijing
- RecruitingSafety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
- Phase
- Early phase 1
- Started
- 2026-07
- Registry
- NCT07767630
Age 1 year to 100 years (registered criteria)
Led by West China HospitalChengdu
- Recruiting68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma
- Phase
- Early phase 1
- Started
- 2026-04
- Registry
- NCT07774533
Age 10 years to 80 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingCT Imaging and Clinical Features to Predict Outcomes in Patients With Gastric Cancer
- Phase
- Not given
- Started
- 2026-04
- Registry
- NCT07776067
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingIparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07776080
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingBecotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07781358
Age 18 years to 80 years (registered criteria)
Led by Eye & ENT Hospital of Fudan UniversityShanghai
- Recruiting5T MRI and Metabolomics-Based Hemorrhage Risk Prediction in Moyamoya Disease
- Phase
- Not given
- Started
- 2026-02
- Registry
- NCT07781579
Age not stated (registered criteria)
Led by Beijing HospitalBeijing
- RecruitingCD38 Targeted -PET/ CT for Multiple Myeloma
- Phase
- N/A
- Started
- 2026-07
- Registry
- NCT07782944
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Guilin Medical UniversityGuilin
- RecruitingInterferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07787273
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei
- RecruitingA Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07788196
Age 18 years to Not stated (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingRadical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Phase
- Phase 3
- Started
- 2026-12
- Registry
- NCT07789184
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an
- RecruitingOral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07793695
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingGPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07795437
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingProphylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07796789
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesChangsha, Fuzhou, Guangzhou
- RecruitingIRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
- Phase
- N/A
- Started
- 2026-05
- Registry
- NCT07799922
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingIparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07801287
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingEffect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07811687
Age 18 years to 80 years (registered criteria)
Led by Northern Jiangsu People's HospitalYangzhou
- RecruitingSacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07811752
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingDynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07819656
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingInspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
- Phase
- Not given
- Started
- 2026-01
- Registry
- NCT07820254
Age 18 years to 80 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingTo Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07822100
Age 18 years to 75 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingEffects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07822711
Age 6 years to 12 years (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingEfgartigimod in Anti-NMDA Receptor Encephalitis.
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07822776
Age 18 years to Not stated (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingImage-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07835087
Age 18 years to 80 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingDual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07838714
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingBiomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07840092
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingInstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-06
- Registry
- NCT07848750
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingSilent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction Cancer
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07849608
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingBEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2026-09
- Registry
- NCT07854652
Age 14 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingAnti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07855640
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingLECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07857668
Age 20 years to 80 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingRadiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07858630
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07863141
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingEfficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya Disease
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07889531
Age 18 years to 70 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingBecotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07892833
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Bengbu Medical UniversityBengbu
- RecruitingDevelopment and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07894107
Age 12 years to 70 years (registered criteria)
Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou
- RecruitingHemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07905066
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingGN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2026-08
- Registry
- NCT07910708
Age 18 years to 75 years (registered criteria)
Led by Pu'er People's HospitalPu'er
- RecruitingPhase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
- Phase
- Phase 1
- Started
- 2026-09
- Registry
- NCT07914556
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Recruiting68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07914764
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingCTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-01
- Registry
- NCT06095154
Age 18 years to 70 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingA Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06356688
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingTCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Registry
- NCT06481735
Age 16 years to 70 years (registered criteria)
Led by Chinese PLA General Hospital; 3 listed hospitals as study sitesBeijing, Tianjin
- RecruitingMobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT06514508
Age 18 years to 78 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingSystemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06519591
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingThe Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
- Phase
- Phase 1
- Started
- 2025-03
- Registry
- NCT06620809
Age 18 years to 65 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT06644781
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou
- RecruitingClinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-01
- Registry
- NCT06676982
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06685887
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
- Phase
- Phase 1
- Started
- 2025-03
- Registry
- NCT06688435
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06689917
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2025-04
- Registry
- NCT06717113
Age 18 years to 80 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingA Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT06730256
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Registry
- NCT06731478
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou
- RecruitingHAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06737913
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Zhengzhou
- RecruitingHepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Registry
- NCT06741020
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingA Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06742892
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha
- RecruitingA Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme
- Phase
- N/A
- Started
- 2025-08
- Registry
- NCT06743477
Age 7 years to 12 years (registered criteria)
Led by Affiliated Hospital of Kunming University of Science and TechnologyKunming
- RecruitingQL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06749899
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan
- RecruitingProphylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC
- Phase
- Phase 3
- Started
- 2025-01
- Registry
- NCT06752239
Age 18 years to 70 years (registered criteria)
Led by Jiangxi Cancer HospitalNanchang
- RecruitingA Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Registry
- NCT06753747
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingSafety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-01
- Registry
- NCT06758713
Age 18 years to 75 years (registered criteria)
Led by Third Affiliated Hospital of Southern Medical UniversityGuangzhou
- RecruitingA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06760819
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai
- RecruitingClinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06762782
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingProtein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT06763848
Age 18 years to 65 years (registered criteria)
Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingNutritional Intervention for Biliary Atresia
- Phase
- N/A
- Started
- 2025-02
- Registry
- NCT06764082
Age 1 day to 3 months (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingNewly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Registry
- NCT06764238
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an
- RecruitingThe Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease
- Phase
- N/A
- Started
- 2025-03
- Registry
- NCT06765499
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingQL1706 Combined With SOX Used in Theperioperative Treatment
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Registry
- NCT06766305
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingStereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06766643
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06769113
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan
- RecruitingHS-10502 Combination Treatment in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT06769425
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingBC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06773312
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Registry
- NCT06780111
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Hefei, Nanchang, Xiamen, Xuzhou, Zhengzhou
- RecruitingLDRT and Chemoimmunotherapy in NPC With Liver Metastasis
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06788002
Age 18 years to 70 years (registered criteria)
Led by Hunan Cancer Hospital; 2 listed hospitals as study sitesChangsha
- RecruitingRobotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2025-02
- Registry
- NCT06791538
Age 18 years to 75 years (registered criteria)
Led by Southwest Hospital, Army Medical UniversityChongqing
- RecruitingA Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2025-01
- Registry
- NCT06791681
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingAnti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
- Phase
- Early phase 1
- Started
- 2025-01
- Registry
- NCT06792799
Age 3 years to Not stated (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- RecruitingDonor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
- Phase
- Early phase 1
- Started
- 2025-01
- Registry
- NCT06793241
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingBCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06793449
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingAponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT06793475
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingTislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2025-06
- Registry
- NCT06793917
Age 18 years to 70 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingCOMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT06796764
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou
- RecruitingCamrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
- Phase
- Phase 2/Phase 3
- Started
- 2025-02
- Registry
- NCT06796803
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan University; 1 listed hospital as study siteHarbin, Shanghai
- RecruitingEfficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06802055
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingEGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Registry
- NCT06802835
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTwo-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06811844
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Xiamen University; 1 listed hospital as study siteHaikou, Xiamen
- RecruitingHAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06812039
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer Center; 2 listed hospitals as study sitesFuzhou, Shanghai, Tianjin
- RecruitingA Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
- Phase
- Phase 3
- Started
- 2025-02
- Registry
- NCT06819826
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingPhase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06827717
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingResearch on Wireless Brain Implant System for General Control of External Devices
- Phase
- N/A
- Started
- 2025-03
- Registry
- NCT06829212
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingHANDLE-a Real World Study on Satralizumab in NMOSD
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT06829524
Age 12 years to Not stated (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingNanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06830018
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang
- RecruitingDevelopment and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06831357
Age not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTo Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT06833983
Age 18 years to 65 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou
- RecruitingA Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06839066
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Nanning, Shenzhen, Wuhan, Zhongshan
- RecruitingContinuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
- Phase
- Phase 3
- Started
- 2025-07
- Registry
- NCT06841172
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingA Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06843889
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Registry
- NCT06844357
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- RecruitingReal-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06846996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou
- RecruitingA Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS
- Phase
- Early phase 1
- Started
- 2025-01
- Registry
- NCT06849609
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingGAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06851247
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Recruiting18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06852807
Age Not stated to 18 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
- Phase
- Phase 1
- Started
- 2025-04
- Registry
- NCT06858813
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingHAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06860490
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingExploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort Study
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06861114
Age 18 years to 75 years (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingA Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06869213
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingComparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06870435
Age 30 years to 69 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingSON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06873659
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi'an
- RecruitingKPD Consolidation After ASCT in NDMM Patients
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Registry
- NCT06879379
Age 18 years to Not stated (registered criteria)
Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing, Shanghai
- RecruitingBCMA CAR-T for Dynamic High-risk Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06880393
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingExploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06881511
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingNewly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Registry
- NCT06882057
Age 1 year to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an
- RecruitingMonoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT06885957
Age 18 years to 65 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2025-03
- Registry
- NCT06890065
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingClinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
- Phase
- Early phase 1
- Started
- 2025-01
- Registry
- NCT06890494
Age 18 years to 70 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingPhase I Study of OriC902 in Treatment of Advanced HCC
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06891742
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing
- RecruitingctDNA-MRD Monitoring After Resection in Gastric Cancer
- Phase
- Not given
- Started
- 2025-04
- Registry
- NCT06893133
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingIndividualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2025-05
- Registry
- NCT06893887
Age 18 years to Not stated (registered criteria)
Led by Nanjing Tianyinshan HospitalNanjing
- RecruitingTACE Combined Surgery for the Resectable Huge HCC
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT06898398
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06901531
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Xining, Zhengzhou
- RecruitingA Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Registry
- NCT06902389
Age 18 years to 75 years (registered criteria)
Led by Eastern Hepatobiliary Surgery HospitalShanghai
- RecruitingLenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06904183
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingLenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06904196
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingNeoadjuvant QL1706 Therapy for ESCC
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06908382
Age 18 years to 75 years (registered criteria)
Led by Shandong Provincial HospitalJinan
- RecruitingSIRT Versus cTACE for Unresectable HCC (CHANCE2506)
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT06909708
Age 18 years to Not stated (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- RecruitingHypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06912074
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingReduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06912698
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06912711
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingJin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF
- Phase
- N/A
- Started
- 2025-09
- Registry
- NCT06914713
Age 40 years to 85 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingMetabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06915389
Age 18 years to 80 years (registered criteria)
Led by Qinghai Red Cross HospitalXining
- RecruitingNeoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2025-04
- Registry
- NCT06925243
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou
- RecruitingA Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT06926283
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changsha, Hangzhou
- RecruitingArsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06933394
Age 18 months to 18 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingReproductive and Mental Health of Patients With Aplastic Anemia
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT06936930
Age 18 years to 40 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingStudy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Registry
- NCT06938880
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingUniversal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases
- Phase
- Early phase 1
- Started
- 2025-06
- Registry
- NCT06939166
Age 18 years to Not stated (registered criteria)
Led by Tianjin Huanhu HospitalTianjin
- RecruitingReal-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT06940102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2025-05
- Registry
- NCT06940960
Age 12 years to 75 years (registered criteria)
Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang
- RecruitingClinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30)
- Phase
- Not given
- Started
- 2025-05
- Registry
- NCT06945718
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingSafety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT06947291
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingNeoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06949033
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou
- RecruitingTextbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2025-04
- Registry
- NCT06950827
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- RecruitingGR1803 Injection in Patients With RRMM
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06952075
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingIparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT06954116
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingJS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06954467
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou
- RecruitingIntravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT06961669
Age 3 years to Not stated (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingA Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- Phase
- Phase 3
- Started
- 2025-07
- Registry
- NCT06963827
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai
- RecruitingCCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
- Phase
- Phase 3
- Started
- 2025-02
- Registry
- NCT06964568
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingBovine Reinforcement in Stomach, Colorectal and Lung Operation
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06968221
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingSafety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06971094
Age 2 years to 12 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Shenzhen, Suzhou, Wuhan
- RecruitingHigh-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed
- Phase
- Early phase 1
- Started
- 2025-04
- Registry
- NCT06972602
Age 1 year to 12 years (registered criteria)
Led by Eye & ENT Hospital of Fudan UniversityShanghai
- RecruitingA Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06976190
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
- Phase
- Early phase 1
- Started
- 2025-05
- Registry
- NCT06976437
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Jiangsu UniversityChangzhou
- RecruitingA Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT06978647
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingFGF19 Overexpression Combination Unified Study in HCC-19
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06978933
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingInvestigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer
- Phase
- Not given
- Started
- 2025-05
- Registry
- NCT06979895
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 1 listed hospital as study siteXi'an
- RecruitingFull-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06985485
Age 15 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingA Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT06986785
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of CT0596 in Plasma Cell Leukemia
- Phase
- Early phase 1
- Started
- 2025-06
- Registry
- NCT06988059
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Registry
- NCT06988488
Age 18 years to Not stated (registered criteria)
Led by Shanghai Fourth People's HospitalShanghai
- RecruitingPersonalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Registry
- NCT06995105
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingPhase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT07000643
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingCorrelation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric Cancer
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT07003334
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingDual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT07003555
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingDual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT07003568
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingBlinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
- Phase
- N/A
- Started
- 2025-02
- Registry
- NCT07003737
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingConversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-10
- Registry
- NCT07007182
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingBCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Registry
- NCT07008885
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingHead-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT07010198
Age 35 years to Not stated (registered criteria)
Led by Zhongshan City People's HospitalZhongshan
- RecruitingDose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT07010237
Age 65 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingVenetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT07012447
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingFOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07012798
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingNeoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07014150
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingA Trial of HRS-5965 Capsule in Primary IgA Nephropathy
- Phase
- Phase 3
- Started
- 2025-06
- Registry
- NCT07014826
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPhase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07018050
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingPIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-06
- Registry
- NCT07018518
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingSafety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Registry
- NCT07022197
Age 18 years to 60 years (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- RecruitingA Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
- Phase
- Phase 3
- Started
- 2025-08
- Registry
- NCT07023315
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Harbin, Shanghai, Shijiazhuang
- RecruitingIBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Registry
- NCT07025889
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingPerioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07026149
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingFeasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
- Phase
- Phase 3
- Started
- 2025-06
- Registry
- NCT07029269
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Lanzhou, Xi'an
- RecruitingNefecon and Ambrisentan in IgA Nephropathy
- Phase
- Phase 4
- Started
- 2025-09
- Registry
- NCT07030894
Age 18 years to 70 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingA Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07032961
Age 45 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Registry
- NCT07035626
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingChemoradiation Plus Iparomlimab Consolidation in Older With ESCC
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07038629
Age 70 years to 90 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)
- Phase
- N/A
- Started
- 2025-06
- Registry
- NCT07039201
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingLenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07047586
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingQL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07049185
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing
- RecruitingA Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07052253
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingPD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
- Phase
- Phase 1
- Started
- 2025-10
- Registry
- NCT07053072
Age 18 years to 70 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingPatient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT07054086
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingGC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT07058298
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Registry
- NCT07058662
Age 4 years to 9 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPredicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT07059936
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingOncolytic Virus in Esophageal Squamous Cell Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Registry
- NCT07061704
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingBITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07062055
Age 18 years to 70 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingAI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07062380
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingTreatment of Moyamoya Disease With iPSC-derived Exosomes
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT07065409
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT07066657
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou
- RecruitingSafety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT07067346
Age 12 months to Not stated (registered criteria)
Led by West China HospitalChengdu
- RecruitingClinical Evaluation of GRAPE Model for Gastric Cancer Screening
- Phase
- Not given
- Started
- 2025-05
- Registry
- NCT07067983
Age 18 years to 80 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingA Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
- Phase
- Phase 2/Phase 3
- Started
- 2025-07
- Registry
- NCT07068165
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingDevelopment and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07068529
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingThe Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating Lymphocytes (TILs) and Histone H3K4me3 in the Tumor Microenvironment
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT07069842
Age 18 years to 75 years (registered criteria)
Led by Changzhi People's Hospital, Changzhi Medical CollegeChangzhi
- RecruitingA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Registry
- NCT07070232
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Hangzhou, Tianjin, Wuhan
- RecruitingCombination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07070479
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Guangzhou, Zhongshan, Zhuhai
- RecruitingStudy of GV20-0251 in Participants With Solid Tumor Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Registry
- NCT07070518
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- RecruitingCD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Registry
- NCT07072494
Age 14 years to 80 years (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingDevelopment and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer:MetBio-GC
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07076979
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingApplication of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07077356
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- RecruitingMulticenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT07078136
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingReal-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT07079150
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an
- RecruitingA Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
- Phase
- Phase 2/Phase 3
- Started
- 2025-10
- Registry
- NCT07082192
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingConfirmatory Clinical Study of HEC585 Tablets in Patients With IPF
- Phase
- Phase 3
- Started
- 2025-10
- Registry
- NCT07082842
Age 40 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingIparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07085234
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingSafety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
- Phase
- Early phase 1
- Started
- 2025-06
- Registry
- NCT07085559
Age 19 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingEffect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT07085988
Age 18 years to Not stated (registered criteria)
Led by Jiangxi Cancer HospitalNanchang
- RecruitingSurufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07086469
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingDeep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT07088354
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07090499
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingShenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2025-05
- Registry
- NCT07098026
Age 18 years to 75 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingLparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07099274
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingLCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- N/A
- Started
- 2025-09
- Registry
- NCT07100067
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Wuhan
- RecruitingTauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07100392
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingTACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07100405
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingAn Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
- Phase
- Early phase 1
- Started
- 2025-09
- Registry
- NCT07101705
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingIparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
- Phase
- Phase 2
- Started
- 2025-10
- Registry
- NCT07101744
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Prediction Model in Pregnant Women With Aplastic Anemia
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07101770
Age 20 years to 50 years; women only (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingSafety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07102901
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Zhengzhou
- RecruitingA Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
- Phase
- Phase 3
- Started
- 2025-08
- Registry
- NCT07103668
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
- Phase
- N/A
- Started
- 2025-05
- Registry
- NCT07104058
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingDevelopment and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07104214
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingEffectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07105579
Age 14 years to 65 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07106671
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07106684
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07106710
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingMRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07106736
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingCD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-06
- Registry
- NCT07106749
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study of GV20-0251 in Advanced or Refractory Solid Tumors
- Phase
- Phase 1
- Started
- 2025-09
- Registry
- NCT07106827
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- RecruitingAutologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Registry
- NCT07109323
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07110571
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shijiazhuang
- RecruitingA Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07114601
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin
- RecruitingThe Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
- Phase
- Phase 1
- Started
- 2025-09
- Registry
- NCT07118319
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07121413
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanjing, Shanghai, Tianjin, Xuzhou, Zhengzhou
- RecruitingAutologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Registry
- NCT07123545
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingMultimodal Deep Learning for Lymph Node Metastasis Prediction and Physician Performance Assessment in T1 Gastric Cancer
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT07124754
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingAssessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07127822
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingToripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07136519
Age 18 years to 65 years (registered criteria)
Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang
- RecruitingPrecise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07137052
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingThe Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07139418
Age 18 years to 85 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingThe Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT07141056
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Guilin Medical University; 1 listed hospital as study siteGuilin, Zhanjiang
- RecruitingSafety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT07142122
Age 18 years to 75 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingDifferent First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07147101
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingThe Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients
- Phase
- Not given
- Started
- 2025-05
- Registry
- NCT07147335
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, University of South ChinaHengyang
- RecruitingExploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07148791
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingPBC Long-term Outcomes Study
- Phase
- Not given
- Started
- 2025-05
- Registry
- NCT07149675
Age not stated (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingThe Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
- Phase
- Phase 4
- Started
- 2025-11
- Registry
- NCT07150624
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingNewly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT07152041
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan
- RecruitingAdaptive Immunotherapy for Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07154069
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingApatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07154082
Age 18 years to 70 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT07157969
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingdCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07162506
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingNeoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07165847
Age 18 years to Not stated (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- RecruitingSafety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer
- Phase
- Early phase 1
- Started
- 2025-10
- Registry
- NCT07166263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- RecruitingClinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Registry
- NCT07169500
Age 18 years to 50 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingComputer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07170345
Age 18 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai
- RecruitingCombination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
- Phase
- N/A
- Started
- 2025-10
- Registry
- NCT07175155
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesBeijing, Hangzhou, Taizhou
- RecruitingThe PRE-VAIL Study
- Phase
- N/A
- Started
- 2025-09
- Registry
- NCT07176624
Age 18 years to Not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingPhase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-11
- Registry
- NCT07176650
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingSerplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-09
- Registry
- NCT07177443
Age 18 years to 65 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingConsolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
- Phase
- Phase 3
- Started
- 2025-09
- Registry
- NCT07177794
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- Phase
- Phase 1
- Started
- 2025-12
- Registry
- NCT07179679
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengde, Chongqing, Guangzhou, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Xi'an
- RecruitingRadiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT07179900
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingThe Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07183150
Age 18 years to 80 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07187440
Age 7 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an
- RecruitingSafety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients
- Phase
- Early phase 1
- Started
- 2025-08
- Registry
- NCT07188012
Age 2 years to 7 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingIvonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07188103
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingPhase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer
- Phase
- Phase 3
- Started
- 2025-08
- Registry
- NCT07188584
Age 18 years to 70 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingSystemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07192185
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingConversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07194005
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT07203404
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
- Phase
- Early phase 1
- Started
- 2025-09
- Registry
- NCT07205315
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingA Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07208058
Age 16 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou
- RecruitingGKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07209813
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Nanchang, Nanjing, Zhengzhou
- RecruitingThe Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07212933
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Phase
- Phase 1
- Started
- 2025-10
- Registry
- NCT07213791
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingClinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
- Phase
- Phase 1
- Started
- 2025-09
- Registry
- NCT07215650
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Guangzhou, Guiyang, Shanghai, Taiyuan, Tianjin, Zhengzhou
- RecruitingSymbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Phase
- Phase 1/Phase 2
- Started
- 2025-12
- Registry
- NCT07227012
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingDeep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07235410
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingDalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07238881
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingStudy to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07239245
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 2 listed hospitals as study sitesBeijing, Shenyang, Zhengzhou
- RecruitingA Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
- Phase
- Early phase 1
- Started
- 2025-12
- Registry
- NCT07240896
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei
- RecruitingTC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
- Phase
- Early phase 1
- Started
- 2025-12
- Registry
- NCT07242417
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingStudy on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2025-12
- Registry
- NCT07243691
Age 18 years to Not stated (registered criteria)
Led by Sir Run Run Shaw HospitalHangzhou
- RecruitingAssessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT07244406
Age 3 years to 25 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study of DEG6498 in Participants With Solid Tumors
- Phase
- Phase 1
- Started
- 2025-11
- Registry
- NCT07244835
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingUniversal CAR-T Cell Therapy for MM
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT07248176
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalShanghai
- RecruitingCAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2025-03
- Registry
- NCT07249073
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingAI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07250347
Age 18 years to 85 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingDistribution Characteristics of Helicobacter Pylori
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07253948
Age 18 years to 80 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingA Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
- Phase
- Phase 1/Phase 2
- Started
- 2025-11
- Registry
- NCT07258979
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Jiangmen, Kunming, Nanchang, Nanning, Shanghai, Shaoguan, Xiamen
- RecruitingA Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-10
- Registry
- NCT07263386
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingPerioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07263919
Lead sponsor is not a listed hospital; 1 listed hospital as study siteXi'an
- RecruitingClinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07266480
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingCamrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
- Phase
- Phase 3
- Started
- 2025-10
- Registry
- NCT07267806
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingTITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
- Phase
- N/A
- Started
- 2025-12
- Registry
- NCT07268131
Age 18 years to 75 years (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingZanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
- Phase
- Phase 4
- Started
- 2025-11
- Registry
- NCT07270835
Age 14 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingJMT106 Injection in the Treatment of Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-09
- Registry
- NCT07275073
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingPhase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07277439
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingInduction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)
- Phase
- Phase 2
- Started
- 2025-10
- Registry
- NCT07277764
Age 18 years to 75 years (registered criteria)
Led by Jiangxi Cancer HospitalNanchang
- RecruitingMultimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Registry
- NCT07282184
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07282353
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingThe Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
- Phase
- Phase 2/Phase 3
- Started
- 2025-10
- Registry
- NCT07285850
Age 18 years to Not stated (registered criteria)
Led by Eastern Hepatobiliary Surgery HospitalShanghai
- RecruitingThe Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
- Phase
- Phase 1/Phase 2
- Started
- 2025-12
- Registry
- NCT07287228
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingIparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07289997
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingThe Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07290010
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingA Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2025-12
- Registry
- NCT07294625
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province Hospital; 4 listed hospitals as study sitesNanjing, Shanghai, Xi'an, Xuzhou, Zhengzhou
- RecruitingNovel Humanized Ferritin-Based NIR Fluorescent Probe for Identifying Sentinel Lymph Node Metastasis in Early Gastric Cancer
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT07294638
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingPDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07294664
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingFIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07296458
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 1 listed hospital as study siteGuangzhou, Xi'an
- RecruitingReal-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT07296627
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07297329
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingClinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer
- Phase
- Phase 1
- Started
- 2025-12
- Registry
- NCT07298200
Age 18 years to 70 years (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- RecruitingClinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07301814
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingIndividualized Neck Cervical Irradiation Prophylaxis Trial of NPC
- Phase
- Phase 3
- Started
- 2025-09
- Registry
- NCT07303023
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Chongqing, Hangzhou, Shanghai
- RecruitingCAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
- Phase
- Phase 1
- Started
- 2025-12
- Registry
- NCT07305116
Age 3 years to Not stated (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- RecruitingRandomised Controlled Trial of Artificial Intelligence-assisted Health Education
- Phase
- N/A
- Started
- 2025-06
- Registry
- NCT07305337
Age 18 years to 90 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- RecruitingHigh-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients
- Phase
- N/A
- Started
- 2025-12
- Registry
- NCT07307560
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingPrevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07311772
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shanghai, Shantou, Wuzhou, Zhuhai
- RecruitingA Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07312188
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingIparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07315854
Age 18 years to 80 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- Recruitingβ-alanine in the Treatment of Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07317414
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College Hospital; 2 listed hospitals as study sitesBeijing, Nanjing, Xuzhou
- RecruitingNeoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT07317609
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Recruiting68Ga-BCMA PET/CT in Multiple Myeloma
- Phase
- Phase 2/Phase 3
- Started
- 2025-12
- Registry
- NCT07319897
Age 18 years to 80 years (registered criteria)
Led by Peking University First Hospital; 2 listed hospitals as study sitesBeijing, Changchun, Shijiazhuang
- RecruitingDEB-TACE vs cTACE in HCC After TIPS
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07322848
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingNWRD06 DNA Plasmid for HCC After Curative Resection.
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07324304
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Harbin
- RecruitingPerioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07325630
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07327034
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou
- RecruitingQL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07327788
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingReduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07328841
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Wuhan, Wuzhou, Zhongshan, Zhuhai
- Recruiting40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07328854
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shantou, Wuzhou, Zhongshan, Zhuhai
- RecruitingSintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07331883
Age 18 years to 75 years (registered criteria)
Led by Ruijin Hospital; 2 listed hospitals as study sitesChangchun, Shanghai
- RecruitingEfcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07337421
Age 18 years to 75 years (registered criteria)
Led by Northern Jiangsu People's HospitalYangzhou
- RecruitingEfficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07337460
Age 18 years to 75 years (registered criteria)
Led by Northern Jiangsu People's HospitalYangzhou
- RecruitingCD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
- Phase
- Early phase 1
- Started
- 2025-12
- Registry
- NCT07337785
Age 18 years to 70 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingProspective Single-Arm Clinical Trial of GO Regimen for HLH.
- Phase
- Phase 2/Phase 3
- Started
- 2025-06
- Registry
- NCT07339345
Age 14 years to 70 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingIntestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07339488
Age 18 years to 75 years (registered criteria)
Led by Shantou University Medical College hospitalsShantou
- RecruitingProton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07340515
Age 18 years to 70 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingAdebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT07353684
Age 18 years to 75 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingNovel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- N/A
- Started
- 2025-11
- Registry
- NCT07359014
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingLaryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07359586
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAdjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07366528
Age 18 years to 80 years (registered criteria)
Led by Ruijin Hospital; 3 listed hospitals as study sitesShanghai
- RecruitingClinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2025-10
- Registry
- NCT07369895
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingAn Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-12
- Registry
- NCT07371663
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Zhengzhou
- RecruitingA Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-06
- Registry
- NCT07376707
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingEfficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Phase
- N/A
- Started
- 2025-12
- Registry
- NCT07377305
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingMDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07391839
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shanghai, Zhengzhou
- RecruitingSafety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07392346
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingRCT of EFTR Versus STER for GIST Treatment
- Phase
- N/A
- Started
- 2025-02
- Registry
- NCT07411118
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPrevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
- Phase
- Phase 3
- Started
- 2025-10
- Registry
- NCT07413809
Age 18 years to 65 years (registered criteria)
Led by Affiliated People's Hospital of Ningbo UniversityNingbo
- RecruitingConstruction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07417800
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingExploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07435454
Age 70 years to Not stated (registered criteria)
Led by Jiangsu Cancer HospitalNanjing
- RecruitingImpact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
- Phase
- Not given
- Started
- 2025-12
- Registry
- NCT07436845
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingCD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07441291
Age 3 years to 79 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07464912
Age 40 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingcfDNA Methylation for Liver Cancer Recurrence Detection
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07466602
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingKC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07481058
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingLetermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis
- Phase
- N/A
- Started
- 2025-10
- Registry
- NCT07488728
Age Not stated to 18 years (registered criteria)
Led by Beijing Children's HospitalBeijing
- RecruitingStudy of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07489534
Age 14 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Registry
- NCT07495215
Age 18 years to 75 years (registered criteria)
Led by Sir Run Run Shaw HospitalHangzhou
- RecruitingEpunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07497165
Age 18 years to 75 years (registered criteria)
Led by Shanxi Bethune HospitalTaiyuan
- RecruitingA Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
- Phase
- N/A
- Started
- 2025-10
- Registry
- NCT07499284
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow University; 2 listed hospitals as study sitesHangzhou, Suzhou, Xuzhou
- RecruitingIL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07509086
Age 18 years to 80 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingShort-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07530094
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- RecruitingComparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07559864
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingFull-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT07564453
Age 15 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingBrain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07578675
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingSintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07581821
Age 18 years to 65 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingEarly Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07585981
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingSingle-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial
- Phase
- N/A
- Started
- 2025-11
- Registry
- NCT07586384
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- RecruitingTo Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07594964
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- RecruitingA IIT Study of 177Lu-DOTA-SNA040
- Phase
- Early phase 1
- Started
- 2025-11
- Registry
- NCT07595237
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingKXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
- Phase
- Phase 1
- Started
- 2025-12
- Registry
- NCT07596693
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07616700
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingExploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07622797
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Henan University of Science and TechnologyLuoyang
- RecruitingSafety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT07652138
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingTAIC FOLFOX for Locally Advanced G/GEJA
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07655024
Age 18 years to Not stated (registered criteria)
Led by Guang'anmen HospitalBeijing
- RecruitingProspective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07725783
Age 10 years to 60 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingThe Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07757165
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingLow-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07763054
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Central South UniversityHaikou
- RecruitingPeg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
- Phase
- N/A
- Started
- 2025-12
- Registry
- NCT07769827
Age 18 years to Not stated (registered criteria)
Led by Jinling HospitalNanjing
- RecruitingA Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07770113
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou University; 1 listed hospital as study siteLuoyang, Zhengzhou
- RecruitingAdebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC
- Phase
- Phase 2
- Started
- 2025-10
- Registry
- NCT07796113
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an
- RecruitingAnlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT07806292
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingPredicting Efficacy of Preoperative Immunotherapy in Advanced Gastric Cancer
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07824479
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingIrreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT07832006
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingNeoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT07867392
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingCandonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07920224
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingPrecision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT04535843
Age 0 years to 90 years (registered criteria)
Led by Huashan Hospital; 1 listed hospital as study siteShanghai
- RecruitingExploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on Multiomics
- Phase
- Not given
- Started
- 2024-03
- Registry
- NCT05812287
Age 18 years to 75 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingFeasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric Cancer
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT05892289
Age 20 years to 80 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingIC Plus Low-dose Radiation Plus Cadonilimab in LANPC
- Phase
- Phase 3
- Started
- 2024-01
- Registry
- NCT05941741
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesGuangzhou, Nanchang, Nanning
- RecruitingA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT05956587
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingThiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06060782
Age 18 years to 65 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06083207
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou
- RecruitingEvaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- Phase
- Phase 2/Phase 3
- Started
- 2024-01
- Registry
- NCT06111638
Age 18 years to Not stated; men only (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Guiyang, Kunming, Suzhou, Tianjin, Wuhan, Xi'an
- RecruitingSHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
- Phase
- Phase 3
- Started
- 2024-01
- Registry
- NCT06123494
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingClinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2024-09
- Registry
- NCT06128252
Age 18 years to 75 years (registered criteria)
Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an
- RecruitingNKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06134960
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingLenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06157996
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 2
- Started
- 2024-02
- Registry
- NCT06172478
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou
- RecruitingCAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT06179524
Age Not stated to 25 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingThe Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
- Phase
- Not given
- Started
- 2024-01
- Registry
- NCT06182657
Age 18 years to Not stated (registered criteria)
Led by Jiangxi Cancer HospitalNanchang
- RecruitingClinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT06194656
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
- Phase
- Phase 3
- Started
- 2024-02
- Registry
- NCT06194734
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingAK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06196697
Age 18 years to 75 years (registered criteria)
Led by Harbin Medical University HospitalHarbin
- RecruitingInvestigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06197776
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingEvaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry Disease
- Phase
- Early phase 1
- Started
- 2024-02
- Registry
- NCT06207552
Age 7 years to 18 years (registered criteria)
Led by Children's Hospital of Fudan UniversityShanghai
- RecruitingCadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06215651
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingDV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- Phase
- Phase 2/Phase 3
- Started
- 2024-02
- Registry
- NCT06221748
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Harbin, Jinan, Kunming, Qingdao, Shanghai, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingAdjuvant vs Surgery Only in Early-stage Recurrent NPC
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06228079
Age 18 years to 75 years (registered criteria)
Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen
- RecruitingThe Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
- Phase
- Not given
- Started
- 2024-04
- Registry
- NCT06228794
Age 18 years to 80 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
- Phase
- Phase 1/Phase 2
- Started
- 2024-02
- Registry
- NCT06232096
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingEarly Detection and Post-operative Monitoring of Gastric Cancer
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT06232395
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingNeoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
- Phase
- Phase 3
- Started
- 2024-07
- Registry
- NCT06235203
Age 18 years to 75 years (registered criteria)
Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen
- RecruitingSafety and Efficacy Study of NGGT003 in Hemophilia A Patients
- Phase
- Early phase 1
- Started
- 2024-01
- Registry
- NCT06238908
Age 18 years to Not stated; men only (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingReduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- Phase
- Phase 3
- Started
- 2024-03
- Registry
- NCT06239727
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang
- RecruitingImmunotherapy for Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2024-03
- Registry
- NCT06241326
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingMyasthenia Gravis Registry in China
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT06241521
Age not stated (registered criteria)
Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou
- RecruitingA Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
- Phase
- Phase 2/Phase 3
- Started
- 2024-02
- Registry
- NCT06241599
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingIndividualized Elective Neck Irradiation in NPC Patients
- Phase
- Phase 3
- Started
- 2024-04
- Registry
- NCT06241612
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingHAIC (Hepatic Artery Infusion Chemotherapy,HAIC)Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT06244225
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06249438
Age 18 years to 70 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingRDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
- Phase
- Phase 2
- Started
- 2024-02
- Registry
- NCT06250959
Age 15 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingEfficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06255210
Age 18 years to Not stated (registered criteria)
Led by Eye & ENT Hospital of Fudan UniversityShanghai
- RecruitingCryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
- Phase
- N/A
- Started
- 2024-02
- Registry
- NCT06265350
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
- Phase
- Early phase 1
- Started
- 2024-01
- Registry
- NCT06267183
Age 18 years to 45 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingAdjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06272214
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingMaintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2024-03
- Registry
- NCT06277050
Age 18 years to 70 years (registered criteria)
Led by Jiangxi Cancer Hospital; 2 listed hospitals as study sitesGanzhou, Nanchang
- RecruitingUTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- N/A
- Started
- 2024-04
- Registry
- NCT06279026
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou
- RecruitingA Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06280105
Age 18 years to 75 years (registered criteria)
Led by Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou
- RecruitingImpact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension
- Phase
- Not given
- Started
- 2024-03
- Registry
- NCT06280313
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Recruitingβ-Thalassemia Treatment With KL003 Cell Injection
- Phase
- Phase 1/Phase 2
- Started
- 2024-04
- Registry
- NCT06280378
Age 3 years to 35 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Tianjin
- RecruitingThe BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06285279
Age 18 years to 65 years (registered criteria)
Led by Jinling HospitalNanjing
- RecruitingA Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis
- Phase
- Not given
- Started
- 2024-03
- Registry
- NCT06287788
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique
- Phase
- N/A
- Started
- 2024-01
- Registry
- NCT06300879
Age 18 years to 75 years (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingTPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06301165
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesDongguan, Foshan, Guangzhou, Shenzhen, Wuhan
- RecruitingRituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06301399
Age 17 years to 79 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingPembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-02
- Registry
- NCT06304350
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingEffectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06306755
Age 50 years to 69 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingPlasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT06307314
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingThe Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
- Phase
- Early phase 1
- Started
- 2024-03
- Registry
- NCT06307600
Age 3 years to 70 years (registered criteria)
Led by First Affiliated Hospital of USTC; 1 listed hospital as study siteHefei, Wuhan
- RecruitingA Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06307925
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
- Phase
- Not given
- Started
- 2024-04
- Registry
- NCT06308328
Age 18 years to Not stated (registered criteria)
Led by Nanfang Hospital; 9 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Shaoguan, Shenzhen, Zhuhai
- RecruitingPhase 2 Study of WGI-0301 for Advanced HCC
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06309485
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan
- RecruitingPrecision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
- Phase
- Phase 4
- Started
- 2024-04
- Registry
- NCT06311929
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingCombination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06313190
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingDe-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2024-03
- Registry
- NCT06313450
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingMetronomic Capecitabine in Stage III Gastric Cancer
- Phase
- Phase 3
- Started
- 2024-03
- Registry
- NCT06313567
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2024-01
- Registry
- NCT06321939
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingSBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06323239
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase
- Phase 1/Phase 2
- Started
- 2024-06
- Registry
- NCT06324357
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingSurvival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
- Phase
- Phase 3
- Started
- 2024-03
- Registry
- NCT06338683
Age 18 years to 80 years (registered criteria)
Led by Qinghai Red Cross HospitalXining
- RecruitingCombination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06339619
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingWeekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06340204
Age 8 years to 40 years (registered criteria)
Led by Peking University People's Hospital; 2 listed hospitals as study sitesBeijing, Jinan
- RecruitingConcurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06341595
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingEfficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06342167
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesAnyang, Fuzhou, Taizhou, Tianjin, Xinxiang, Yinchuan
- RecruitingClinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
- Phase
- N/A
- Started
- 2024-04
- Registry
- NCT06343090
Age 1 year to 70 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingFecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2024-04
- Registry
- NCT06346093
Age 18 years to Not stated (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingCD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
- Phase
- Early phase 1
- Started
- 2024-05
- Registry
- NCT06346912
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingNeoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06349317
Age 18 years to 75 years (registered criteria)
Led by Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou
- RecruitingAdebrelimab and Chemoradiotherapy in High-risk LANPC
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06349889
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesChengdu, Guangzhou, Xiamen
- RecruitingA Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06349980
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingDEB-TACE Prior to Liver Transplantation in the Treatment of HCC
- Phase
- Phase 4
- Started
- 2024-10
- Registry
- NCT06353126
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingPPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06354140
Age 18 years to 75 years (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- RecruitingCD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
- Phase
- N/A
- Started
- 2024-02
- Registry
- NCT06355739
Age 3 years to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingAnti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT06360042
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingCombination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06363006
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingSafety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
- Phase
- Phase 1
- Started
- 2024-07
- Registry
- NCT06371040
Age 18 years to 80 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingA Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2024-08
- Registry
- NCT06371157
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Hangzhou, Nanjing, Zhengzhou
- RecruitingStudy of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-05
- Registry
- NCT06375044
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Tianjin, Zhengzhou
- RecruitingBiomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06382103
Age not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingPET Imaging Study of 68Ga-NB381 in Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2024-04
- Registry
- NCT06385652
Age 18 years to 90 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingNeoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06385730
Age 76 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingEfficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06387121
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingPretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06389201
Age 20 years to 70 years (registered criteria)
Led by Affiliated Hospital of Nantong UniversityNantong
- RecruitingCIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
- Phase
- N/A
- Started
- 2024-05
- Registry
- NCT06389305
Age 1 year to 39 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingPhase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06389422
Age 18 years to 90 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingEvaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug
- Phase
- Phase 1/Phase 2
- Started
- 2024-04
- Registry
- NCT06391736
Age 6 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingDecitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06393985
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingSintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06397222
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingDEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06397235
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingFMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06405113
Age 18 years to 80 years (registered criteria)
Led by Changzhou No.2 People's HospitalChangzhou
- RecruitingCadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06406634
Age 18 years to 75 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingStudy of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2024-06
- Registry
- NCT06407947
Age 18 years to Not stated (registered criteria)
Led by Changzheng HospitalShanghai
- RecruitingShort-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
- Phase
- Not given
- Started
- 2024-03
- Registry
- NCT06408584
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingTreatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
- Phase
- Phase 4
- Started
- 2024-06
- Registry
- NCT06409702
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingSintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06413342
Age 70 years to 85 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingA Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06413654
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou
- RecruitingA Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06415669
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingFruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
- Phase
- Not given
- Started
- 2024-04
- Registry
- NCT06417892
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
- Phase
- Early phase 1
- Started
- 2024-10
- Registry
- NCT06418659
Age 18 years to Not stated (registered criteria)
Led by Changzheng HospitalShanghai
- RecruitingInduction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06421376
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 2 listed hospitals as study sitesAnyang, Beijing, Xinxiang
- RecruitingEvaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
- Phase
- Phase 1/Phase 2
- Started
- 2024-05
- Registry
- NCT06421831
Age 2 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingTargeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma
- Phase
- Early phase 1
- Started
- 2024-12
- Registry
- NCT06424301
Age 6 months to Not stated (registered criteria)
Led by Eye & ENT Hospital of Fudan UniversityShanghai
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingResearch on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06429891
Age 18 years to 70 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingNeoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06430658
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingRecurrent Liver Cancer: Reconceptualization and Reevaluation
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06430983
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Nanjing Medical UniversityNanjing
- RecruitingA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06437522
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingEfficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
- Phase
- Phase 3
- Started
- 2024-05
- Registry
- NCT06438627
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingDiagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06445088
Age not stated (registered criteria)
Led by Sun Yat-sen University Cancer Center; 4 listed hospitals as study sitesFuzhou, Guangzhou, Nanning, Wuzhou, Zhongshan
- RecruitingCD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
- Phase
- Phase 1
- Started
- 2024-05
- Registry
- NCT06445803
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanchang, Shanghai
- RecruitingFruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06446154
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingLow-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06446726
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06447597
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an, Zunyi
- RecruitingInaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06450067
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingInduction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06452602
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingAdjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06454578
Age 18 years to Not stated (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingGP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06455410
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 7 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen
- RecruitingClinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2024-07
- Registry
- NCT06461624
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingEfficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06461910
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingDeep Learning-based sbORN Diagnostic Model
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06463392
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06463587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi
- RecruitingA Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06463834
Age 18 years to 75 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingStapler Reinforcement Patches Compared to Standard Staplers in Gastrojejunostomy
- Phase
- N/A
- Started
- 2024-05
- Registry
- NCT06464978
Age 18 years to 85 years (registered criteria)
Led by Nanchong Central HospitalNanchong
- RecruitingA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Registry
- NCT06465069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingA Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
- Phase
- Phase 1
- Started
- 2024-01
- Registry
- NCT06465550
Age 3 years to 35 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Nanning, Shanghai
- RecruitingNeoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT06467799
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingSynergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06468280
Age 18 years to 79 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Registry
- NCT06469944
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Urumqi, Xiamen, Zhengzhou
- RecruitingPalliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2024-06
- Registry
- NCT06470256
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingClinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06472713
Age 18 years to 70 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingEfficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06474520
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06475300
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingBackline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib
- Phase
- N/A
- Started
- 2024-01
- Registry
- NCT06478927
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Long-term Follow-up Study in Participants Who Received CS-101
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06479616
Age 3 years to 17 years (registered criteria)
Led by Children's Hospital of Fudan UniversityShanghai
- RecruitingEfficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06481228
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingEfficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06481241
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingCheckpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06482801
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Clinical Study of SHR-9539 in Patients With Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-08
- Registry
- NCT06484777
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- RecruitingPurinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Registry
- NCT06484829
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- RecruitingTACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2024-08
- Registry
- NCT06485466
Age 18 years to 80 years (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- RecruitingShort Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06487429
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingAK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06489197
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingLenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
- Phase
- Phase 3
- Started
- 2024-08
- Registry
- NCT06492395
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingNeoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06492408
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingSafety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
- Phase
- Early phase 1
- Started
- 2024-07
- Registry
- NCT06497361
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingSafety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
- Phase
- Early phase 1
- Started
- 2024-07
- Registry
- NCT06497387
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06497738
Age 65 years to Not stated (registered criteria)
Led by Jiangsu Province Hospital; 2 listed hospitals as study sitesChangzhou, Nanjing, Nantong
- RecruitingA Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
- Phase
- Phase 4
- Started
- 2024-06
- Registry
- NCT06498089
Age 18 years to 65 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingAdjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06498622
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingA Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Registry
- NCT06500052
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingBiomarkers in Autoimmune Disease of Nervous System
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06502015
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingTo Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2024-08
- Registry
- NCT06504732
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shenyang
- RecruitingA Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06506292
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingBlinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
- Phase
- Phase 1
- Started
- 2024-04
- Registry
- NCT06507514
Age 15 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingEvaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST
- Phase
- N/A
- Started
- 2024-05
- Registry
- NCT06507683
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Chongqing Medical UniversityChongqing
- RecruitingA Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06508983
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingNimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06509009
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingNeoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma(CRIS-2 Trial)
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06509568
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingPerioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06510010
Age 18 years to 75 years (registered criteria)
Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingEfficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06510283
Age 14 years to Not stated (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingAdebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06510660
Age 18 years to 70 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingCVI Alterations in FD: a Prospective, Multicenter, Observational Cohort Study
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06512571
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingHRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-10
- Registry
- NCT06515314
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingOnline Adaptive Radiotherapy for Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2024-05
- Registry
- NCT06516133
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingProspective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06519578
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingComparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
- Phase
- Phase 3
- Started
- 2024-08
- Registry
- NCT06520176
Age 18 years to 75 years (registered criteria)
Led by Affiliated People's Hospital of Ningbo University; 6 listed hospitals as study sitesHangzhou, Ningbo, Taizhou, Wenzhou
- RecruitingA Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Registry
- NCT06530251
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Jinan
- RecruitingA Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-08
- Registry
- NCT06531486
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Phase
- Phase 3
- Started
- 2024-11
- Registry
- NCT06532006
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xining, Xuzhou, Yinchuan, Zhengzhou
- RecruitingEndoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
- Phase
- N/A
- Started
- 2024-03
- Registry
- NCT06533267
Age 18 years to 75 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingAnti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06537908
Age 18 years to 90 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingEvaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06539624
Age 7 years to Not stated (registered criteria)
Led by Children's Hospital, Zhejiang University School of Medicine; 1 listed hospital as study siteHangzhou, Shanghai
- RecruitingIntestinal Flora and Immunity in Monoclonal Gammopathy Patients
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06539832
Age 45 years to Not stated (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingSun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
- Phase
- Not given
- Started
- 2024-01
- Registry
- NCT06541626
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingStudy on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-09
- Registry
- NCT06542796
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingPreliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer
- Phase
- Not given
- Started
- 2024-01
- Registry
- NCT06543108
Age 18 years to 90 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingEarly-stage Detection of Liver Cancer by Proteins in Peripheral Blood
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT06544083
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAblation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06550921
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingBlinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06554626
Age 40 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06555471
Age 75 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
- Phase
- Phase 1
- Started
- 2024-12
- Registry
- NCT06556394
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Hangzhou
- RecruitingDisitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT06560528
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingIndividualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06561178
Age not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTriple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06561399
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial Hospital; 2 listed hospitals as study sitesFuzhou
- RecruitingSintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2024-02
- Registry
- NCT06563869
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingOral Fecal Microbiota Transplantation in Advanced Hepatocellular Carcinoma After Progression on ICI-TKI Therapy
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT06563947
Age 18 years to 75 years (registered criteria)
Led by Shenzhen Third People's HospitalShenzhen
- RecruitingA Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT06564272
Age 12 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingNeoadjuvant Triple Therapy for Resectable HCC
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06569498
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen
- RecruitingDisitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Registry
- NCT06572319
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingA Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-06
- Registry
- NCT06574568
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou
- RecruitingAdding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06574698
Age 1 year to 21 years (registered criteria)
Led by Guangzhou Women and Children's Medical CenterGuangzhou
- RecruitingAdbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06576973
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingStudy of YK012 in B-cell Acute Lymphoblastic Leukemia
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Registry
- NCT06580301
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Guangzhou, Guiyang, Hangzhou, Nanchang, Xuzhou
- RecruitingImmune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT06580574
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingBridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06581081
Age 12 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingPostoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06581315
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingChimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT06581640
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingLymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06596954
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingProximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
- Phase
- N/A
- Started
- 2024-03
- Registry
- NCT06597227
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingThe Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06597526
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingBiomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06601309
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingTriple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06602011
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen
- RecruitingImmunoPET Imaging of Pancreatic Cancer
- Phase
- N/A
- Started
- 2024-11
- Registry
- NCT06602037
Age 18 years to 70 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingNeoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
- Phase
- N/A
- Started
- 2024-01
- Registry
- NCT06602843
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingmFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
- Phase
- Phase 2
- Started
- 2024-02
- Registry
- NCT06607107
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingEfficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Registry
- NCT06607419
Age 1 month to 18 years (registered criteria)
Led by Shanghai Children's Medical Center; 1 listed hospital as study siteHefei, Shanghai
- RecruitingCombination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06608732
Age 16 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingThe Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06609850
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingdTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06609863
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingDonafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06609876
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingStudy of IBI363 in Patients with Advanced First-line Gastric Cancer
- Phase
- Phase 1
- Started
- 2024-10
- Registry
- NCT06610799
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingConcurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
- Phase
- Phase 1
- Started
- 2024-08
- Registry
- NCT06611150
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)
- Phase
- Phase 3
- Started
- 2024-10
- Registry
- NCT06618664
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei
- RecruitingTIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06622031
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingCorrelation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06623474
Age 18 years to 80 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingPhase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06631391
Age 1 day to 18 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Phase 2 Clinical Study of ABSK061 and ABSK043
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06632262
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingAI-Assisted Non-Contrast CT for Multi-Cancer Screening
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06632886
Age 18 years to Not stated (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingCD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia
- Phase
- Early phase 1
- Started
- 2024-10
- Registry
- NCT06633328
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingBenmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06637163
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 4 listed hospitals as study sitesHangzhou, Shanghai, Shantou, Shenyang, Tianjin
- RecruitingA Study of Olverembatinib in SDH-deficient GIST.
- Phase
- Phase 3
- Started
- 2024-11
- Registry
- NCT06640361
Age 12 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingHAIC Compared With TACE in Huge Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2024-10
- Registry
- NCT06641713
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingEvaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy
- Phase
- Early phase 1
- Started
- 2024-07
- Registry
- NCT06641895
Age 4 years to 8 years; men only (registered criteria)
Led by Shanghai Children's Medical CenterShanghai
- RecruitingA Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
- Phase
- Phase 1
- Started
- 2024-10
- Registry
- NCT06644118
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAblation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2024-10
- Registry
- NCT06644430
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingSingle-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
- Phase
- Phase 2/Phase 3
- Started
- 2024-11
- Registry
- NCT06644937
Age 18 years to 75 years (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingFruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06646588
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingA Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson Disease
- Phase
- Early phase 1
- Started
- 2024-09
- Registry
- NCT06650319
Age 10 years to 60 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingCadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06650332
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingUmbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06650553
Age 6 years to 75 years (registered criteria)
Led by Shanxi Bethune HospitalTaiyuan
- RecruitingClinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
- Phase
- Early phase 1
- Started
- 2024-11
- Registry
- NCT06652243
Age 18 years to 70 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingCirculating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06653062
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingEfficacy and Safety of Telitacicept in IgAN
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06654596
Age 18 years to 70 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingIMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric Cancer
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06662110
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingAdebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06663059
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingClinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06671236
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingNeoantigen Vaccines in Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06675201
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingUnder Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
- Phase
- Phase 3
- Started
- 2024-07
- Registry
- NCT06675214
Age 18 years to 65 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingA Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
- Phase
- Not given
- Started
- 2024-10
- Registry
- NCT06676007
Age 18 years to 75 years (registered criteria)
Led by Sichuan Provincial People's HospitalChengdu
- RecruitingTDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
- Phase
- Phase 3
- Started
- 2024-11
- Registry
- NCT06676449
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06676722
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingApplication of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06679244
Age 18 years to 80 years (registered criteria)
Led by Huashan Hospital; 2 listed hospitals as study sitesShanghai
- RecruitingConversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06682156
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingStudy of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06684600
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingMts105 for Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06689540
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingCharacteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06690593
Age 45 years to Not stated (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingIntravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-02
- Registry
- NCT06694636
Age 25 years to 75 years (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- RecruitingAllogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
- Phase
- Early phase 1
- Started
- 2024-12
- Registry
- NCT06696833
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingRisk Stratification and MRD-driven Maintenance for MM After ASCT
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06697483
Age 18 years to Not stated (registered criteria)
Led by Peking University People's Hospital; 2 listed hospitals as study sitesBeijing, Harbin
- RecruitingTrilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2024-04
- Registry
- NCT06698692
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06700395
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Shanghai
- RecruitingIntegrative Analysis of Exosome-Mediated Single-Cell Transcriptomics and Proteomics in Gastric Cardia Cancer
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06702891
Age 18 years to Not stated (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingY-90 SIRT for Unresectable HCC Larger Than 7cm
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06707233
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06709417
Age 20 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingTrifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06711471
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingEffect of Premedication With Pronase on Mucosal Cleanliness During EGD
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06713421
Age 18 years to 70 years (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingTrilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06714383
Age 14 years to 70 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingTarget-specific immunoPET Imaging of Digestive System Carcinoma
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06715839
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingInaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06718244
Age 16 years to 70 years (registered criteria)
Led by Ruijin HospitalShanghai
- Recruitinga Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
- Phase
- Early phase 1
- Started
- 2024-12
- Registry
- NCT06718270
Age 18 years to Not stated (registered criteria)
Led by Changzheng HospitalShanghai
- RecruitingLongitudinal Cohort of Thrombosis and Hemostasis Diseases
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06727669
Age not stated (registered criteria)
Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou
- RecruitingAnalysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06728878
Age 18 years to 85 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAnalysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06728891
Age 18 years to 85 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingFirst-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06730373
Age 18 years to 75 years (registered criteria)
Led by Qilu Hospital of Shandong University; 7 listed hospitals as study sitesJinan, Linyi, Qingdao, Yantai, Zhengzhou, Zibo
- RecruitingClinical Study of Super Transplantation in the Treatment of Severe β-thalassemia
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06734520
Age 7 years to 10 years (registered criteria)
Led by Guangzhou Women and Children's Medical CenterGuangzhou
- RecruitingCD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Registry
- NCT06735495
Age 3 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingExploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric Cancer
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06736847
Age 18 years to 85 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingXELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
- Phase
- Phase 1/Phase 2
- Started
- 2024-12
- Registry
- NCT06742411
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingPD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06742424
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingBlinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06742515
Age 15 years to 59 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingBCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06745687
Age 18 years to 78 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingThe Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06746194
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingSafety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06748352
Age 18 years to 80 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingMCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
- Phase
- N/A
- Started
- 2024-01
- Registry
- NCT06748690
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingChimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
- Phase
- Phase 1
- Started
- 2024-12
- Registry
- NCT06751134
Age 1 year to 12 years (registered criteria)
Led by Children's Hospital of Nanjing Medical UniversityNanjing
- RecruitingCD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
- Phase
- Phase 1
- Started
- 2024-10
- Registry
- NCT06752785
Age 1 year to 18 years (registered criteria)
Led by Guangzhou Women and Children's Medical CenterGuangzhou
- RecruitingVenetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06754267
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingFenofibrate in Primary Biliary Cholangitis: a Real World Study
- Phase
- Phase 3
- Started
- 2024-01
- Registry
- NCT06755151
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingFenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study
- Phase
- Phase 3
- Started
- 2024-01
- Registry
- NCT06755541
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingIntraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Registry
- NCT06759064
Age 18 years to 75 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingA Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06760858
Age 18 years to 80 years (registered criteria)
Led by Southwest Hospital, Army Medical UniversityChongqing
- RecruitingClinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS)
- Phase
- N/A
- Started
- 2024-03
- Registry
- NCT06765564
Age 18 years to 60 years (registered criteria)
Led by Shanghai East Hospital, Tongji University; 1 listed hospital as study siteShanghai
- RecruitingA Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
- Phase
- Phase 1
- Started
- 2024-12
- Registry
- NCT06772766
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHaikou, Nanning
- RecruitingA Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2024-08
- Registry
- NCT06776770
Age 18 years to Not stated (registered criteria)
Led by Cancer Hospital CAMS – ShenzhenShenzhen
- RecruitingA First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-12
- Registry
- NCT06783569
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shenyang
- RecruitingThe Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06786169
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Recruiting"Xijiang Project" Screening Cohort for NPC
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06787456
Age 30 years to 69 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingFluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer(IDEAL Stage 2b)
- Phase
- N/A
- Started
- 2024-02
- Registry
- NCT06788548
Age 18 years to 80 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingClinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06791083
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- RecruitingLow-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06791148
Age 18 years to 75 years (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- RecruitingBCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06794008
Age 18 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingStudy on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06817434
Age 18 years to 60 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingA Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06818838
Age 18 years to 60 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Taiyuan, Tianjin
- RecruitingHetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06818916
Age Not stated to 18 years (registered criteria)
Led by Beijing Children's HospitalBeijing
- RecruitingStudy of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Registry
- NCT06821048
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingSafety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06826079
Age 18 years to 70 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06829147
Age not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingStudy on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06832839
Age 18 years to 60 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingSafety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
- Phase
- Phase 1/Phase 2
- Started
- 2024-12
- Registry
- NCT06836505
Age 1 year to 50 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteDongguan, Guangzhou
- RecruitingNovel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06849180
Age 18 years to Not stated (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- RecruitingBaricitinib in the Treatment of Intestinal Behçet's Syndrome
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06849908
Age 18 years to 65 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingTrop2-targeted immunoPET Imaging of Solid Tumors
- Phase
- Phase 2/Phase 3
- Started
- 2024-12
- Registry
- NCT06851663
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingCD70-targeted immunoPET Imaging of Malignant Cancers
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06852638
Age 18 years to 80 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingPlasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06864221
Age 18 years to 80 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingSafety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
- Phase
- Phase 3
- Started
- 2024-11
- Registry
- NCT06867991
Age 12 years to Not stated (registered criteria)
Led by Third Affiliated Hospital of Soochow University; 1 listed hospital as study siteChangzhou, Zhengzhou
- RecruitingEnergy CT in Imaging and Diagnosis of Gastric Cancer
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06869694
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingNanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Registry
- NCT06880913
Age 12 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingThe Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06881043
Age 18 years to 75 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingRobotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06895447
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingEvaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients With Duchenne Muscular Dystrophy
- Phase
- Early phase 1
- Started
- 2024-10
- Registry
- NCT06900049
Age 4 years to 8 years; men only (registered criteria)
Led by Shanghai Children's Medical CenterShanghai
- RecruitingOptimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2/Phase 3
- Started
- 2024-01
- Registry
- NCT06907602
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingThe Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Registry
- NCT06911710
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- RecruitingA Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
- Phase
- Phase 1
- Started
- 2024-09
- Registry
- NCT06927466
Age 3 years to 25 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou
- RecruitingThe Effect of Different Digestive Tract Reconstruction Methods on Postoperative Quality of Life After Proximal Gastrectomy
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06929949
Age 18 years to 75 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingA Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
- Phase
- Phase 4
- Started
- 2024-12
- Registry
- NCT06930573
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingCDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
- Phase
- Early phase 1
- Started
- 2024-12
- Registry
- NCT06937567
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingNimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06988956
Age 75 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2024-09
- Registry
- NCT06999031
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Nanchang UniversityNanchang
- RecruitingNeoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT07016724
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingPost-operative Monitoring of Gastric Cancer
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT07026240
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingLong-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT07028970
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Tianjin, Wuhan, Zhengzhou
- RecruitingEfficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy
- Phase
- N/A
- Started
- 2024-11
- Registry
- NCT07056010
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingDigital Early Warning System for Acute Lung Injury in Liver Surgery
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT07070362
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Chongqing
- RecruitingAn Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT07101237
Age 18 years to 70 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingEffect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT07119463
Age 18 years to 80 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingClinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT07195500
Age 6 months to Not stated (registered criteria)
Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing
- RecruitingAdebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT07309185
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingFruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2024-02
- Registry
- NCT07334431
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingThe Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut Microbiota
- Phase
- Not given
- Started
- 2024-03
- Registry
- NCT07400354
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAdebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT07430579
Age 18 years to 80 years (registered criteria)
Led by Second Hospital of Shandong University; 1 listed hospital as study siteJinan
- RecruitingEfficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
- Phase
- Phase 3
- Started
- 2024-04
- Registry
- NCT07437404
Age Not stated to 6 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingNeoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT07437898
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Putian UniversityPutian
- RecruitingFamily-Based Moyamoya Susceptibility and Early Detection
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT07517354
Age not stated (registered criteria)
Led by Beijing Tiantan Hospital; 1 listed hospital as study siteBeijing
- RecruitingA Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT07547787
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingEfficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2024-04
- Registry
- NCT07584889
Age 18 years to 75 years (registered criteria)
Led by Shenzhen University General HospitalShenzhen
- RecruitingAn Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- Phase
- Phase 1/Phase 2
- Started
- 2024-05
- Registry
- NCT07644832
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Hefei, Jinan, Lanzhou, Taiyuan, Xi'an, Zhengzhou
- RecruitingTumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
- Phase
- Phase 1
- Started
- 2024-09
- Registry
- NCT07648069
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingCohort Study on Neuroimmune Diseases in the Reproductive Age
- Phase
- Not given
- Started
- 2024-04
- Registry
- NCT07653984
Age 20 years to 55 years; women only (registered criteria)
Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingBlinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
- Phase
- Phase 1
- Started
- 2024-12
- Registry
- NCT07677878
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingNeoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT07699185
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingHelicobacter Pylori Infection Status and Pathological Features for Predicting Gastric Cancer Biological Behavior and Prognosis: A Real-World Observational Study
- Phase
- Not given
- Started
- 2024-01
- Registry
- NCT07724496
Age 18 years to 80 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingValidating a Medical AI Fine-Tuning Platform for Major Diseases
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT07795645
Age 18 years to Not stated (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingMultimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
- Phase
- Not given
- Started
- 2024-10
- Registry
- NCT07838415
Age 18 years to 80 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingTEAS for Gastrectomy Recovery
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT07898293
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Qingdao University; 2 listed hospitals as study sitesQingdao, Weifang, Yantai
- RecruitingAspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
- Phase
- Phase 4
- Started
- 2024-02
- Registry
- NCT07907211
Age 18 years to 70 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Registry
- NCT07923214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Fuzhou, Shanghai
- RecruitingPostoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy
- Phase
- N/A
- Started
- 2023-05
- Registry
- NCT03734952
Age 18 years to 65 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingPhase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Registry
- NCT05319639
Age 18 years to 75 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Phase
- Phase 1/Phase 2
- Started
- 2023-05
- Registry
- NCT05319730
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Shanghai, Xiamen, Xinxiang, Zhengzhou
- RecruitingDownstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT05475613
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
- Phase
- Phase 3
- Started
- 2023-01
- Registry
- NCT05489289
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingSafety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Registry
- NCT05565807
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou
- RecruitingTransarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1
- Phase
- Phase 3
- Started
- 2023-03
- Registry
- NCT05593458
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingStereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC
- Phase
- N/A
- Started
- 2023-05
- Registry
- NCT05596630
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingCamrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2023-01
- Registry
- NCT05613478
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Registry
- NCT05667506
Age 3 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChongqing, Guangzhou, Hefei, Nanchang, Nanjing, Tianjin, Wuhan, Xuzhou
- RecruitingPh1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT05671822
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingScreening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
- Phase
- Not given
- Started
- 2023-01
- Registry
- NCT05686447
Age not stated (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingTislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT05687357
Age 18 years to 75 years (registered criteria)
Led by Nanjing Drum Tower Hospital; 2 listed hospitals as study sitesNanjing, Taiyuan, Wuhan
- RecruitingTislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2023-05
- Registry
- NCT05699655
Age 18 years to 75 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingAPG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Registry
- NCT05701306
Age 5 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Tianjin, Wuhan
- RecruitingPrediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
- Phase
- Not given
- Started
- 2023-01
- Registry
- NCT05722275
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Kunming, Taiyuan, Zhengzhou
- RecruitingCamrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT05738434
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingPrevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
- Phase
- N/A
- Started
- 2023-02
- Registry
- NCT05738980
Age 18 years to 75 years (registered criteria)
Led by Beijing HospitalBeijing
- RecruitingFenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- Phase
- Phase 2/Phase 3
- Started
- 2023-02
- Registry
- NCT05749822
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan'an, Zhengzhou
- RecruitingAtezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT05751343
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingApatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
- Phase
- N/A
- Started
- 2023-02
- Registry
- NCT05751733
Age 18 years to Not stated (registered criteria)
Led by Xiangya HospitalChangsha
- RecruitingFenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
- Phase
- Phase 3
- Started
- 2023-02
- Registry
- NCT05751967
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an
- RecruitingA Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- Phase
- Phase 1
- Started
- 2023-03
- Registry
- NCT05759793
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
- Phase
- Early phase 1
- Started
- 2023-02
- Registry
- NCT05762510
Age 5 years to 35 years (registered criteria)
Led by First Affiliated Hospital of Guangxi Medical UniversityNanning
- RecruitingClinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
- Phase
- Phase 2
- Started
- 2023-05
- Registry
- NCT05775042
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingStudy of Comparing of With and Without Sequential Therapy of S-1
- Phase
- Phase 3
- Started
- 2023-01
- Registry
- NCT05813015
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingEvaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Registry
- NCT05824169
Age 0 months to 6 months (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenyang, Suzhou
- RecruitingARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT05830123
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou
- RecruitingWhole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2023-07
- Registry
- NCT05833594
Age 18 years to 85 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingTocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT05845723
Age 18 years to 65 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingPreoperative Serum FGF19 in the Prognosis of Biliary Atresia
- Phase
- Not given
- Started
- 2023-10
- Registry
- NCT05848310
Age not stated (registered criteria)
Led by Children's Hospital of Fudan UniversityShanghai
- RecruitingGemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05854849
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTwo Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05860868
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
- RecruitingDigitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
- Phase
- Not given
- Started
- 2023-03
- Registry
- NCT05870969
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingReduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05877872
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingScreening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2023-02
- Registry
- NCT05884983
Age 30 years to 69 years (registered criteria)
Led by Zhongshan City People's HospitalZhongshan
- RecruitingITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
- Phase
- Phase 4
- Started
- 2023-11
- Registry
- NCT05888870
Age 14 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingEffect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
- Phase
- N/A
- Started
- 2023-06
- Registry
- NCT05892354
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Guangxi Medical University; 13 listed hospitals as study sitesFuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Liuzhou, Nanchang, Nanning, Wuzhou
- RecruitingInfluence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2023-05
- Registry
- NCT05894369
Age 18 years to 80 years (registered criteria)
Led by Renmin Hospital of Wuhan UniversityWuhan
- RecruitingPhase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT05917431
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingComparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2023-04
- Registry
- NCT05918094
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 7 listed hospitals as study sitesChengdu, Dalian, Guangzhou, Harbin, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2023-07
- Registry
- NCT05919030
Age 18 years to Not stated (registered criteria)
Led by Renmin Hospital of Wuhan UniversityWuhan
- RecruitingLenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
- Phase
- Phase 2
- Started
- 2023-07
- Registry
- NCT05920863
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingClinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
- Phase
- Phase 4
- Started
- 2023-01
- Registry
- NCT05923905
Age 18 years to 80 years (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingPreventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy
- Phase
- N/A
- Started
- 2023-07
- Registry
- NCT05925309
Age 14 days to 90 days (registered criteria)
Led by Children's Hospital of Fudan UniversityShanghai
- RecruitingGPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2023-01
- Registry
- NCT05926726
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
- Phase
- Phase 2
- Started
- 2023-07
- Registry
- NCT05934331
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPostoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-09
- Registry
- NCT05937438
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingA Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
- Phase
- Not given
- Started
- 2023-05
- Registry
- NCT05938309
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingMinimally Residual of Esophageal Cancer 001
- Phase
- Not given
- Started
- 2023-02
- Registry
- NCT05952661
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingLenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2023-09
- Registry
- NCT05954897
Age 18 years to Not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingThe Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric
- Phase
- Not given
- Started
- 2023-08
- Registry
- NCT05956847
Age 18 years to 80 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingThe China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
- Phase
- Not given
- Started
- 2023-07
- Registry
- NCT05965115
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingHelical Tomotherapy in Multiple Myeloma
- Phase
- N/A
- Started
- 2023-06
- Registry
- NCT05970198
Age 18 years to 75 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- RecruitingSingle Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2023-11
- Registry
- NCT05970666
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingAdjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
- Phase
- Phase 2
- Started
- 2023-01
- Registry
- NCT05975749
Age 20 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingRadiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2023-01
- Registry
- NCT05978193
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest Hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
- Phase
- Phase 2
- Started
- 2023-08
- Registry
- NCT05979363
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingAdjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
- Phase
- Phase 1
- Started
- 2023-08
- Registry
- NCT05984342
Age 18 years to 70 years (registered criteria)
Led by Shantou University Medical College hospitalsShantou
- RecruitingTACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
- Phase
- N/A
- Started
- 2023-08
- Registry
- NCT05984511
Age 18 years to 75 years (registered criteria)
Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingSintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
- Phase
- Phase 3
- Started
- 2023-08
- Registry
- NCT05985798
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingReducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2023-08
- Registry
- NCT05994170
Age 18 years to 70 years (registered criteria)
Led by Zhongshan City People's HospitalZhongshan
- RecruitingSIRT for Potentially Resectable HCC
- Phase
- N/A
- Started
- 2023-08
- Registry
- NCT05994859
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
- Phase
- Phase 2
- Started
- 2023-11
- Registry
- NCT06008054
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingClinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT06013618
Age 12 months to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingDoxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2023-10
- Registry
- NCT06017895
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingPhase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
- Phase
- Phase 2
- Started
- 2023-09
- Registry
- NCT06023758
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingGNT Induction Treatment in Locally Advanced NPC
- Phase
- Phase 3
- Started
- 2023-09
- Registry
- NCT06026878
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingPerioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
- Phase
- Phase 2
- Started
- 2023-09
- Registry
- NCT06031285
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingAI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- Phase
- Not given
- Started
- 2023-09
- Registry
- NCT06035250
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou
- RecruitingCardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
- Phase
- Not given
- Started
- 2023-11
- Registry
- NCT06039735
Age 18 years to 70 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingConcurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
- Phase
- Phase 3
- Started
- 2023-10
- Registry
- NCT06041477
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingFunctional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia
- Phase
- Not given
- Started
- 2023-10
- Registry
- NCT06041659
Age 18 years to 65 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingA Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer
- Phase
- N/A
- Started
- 2023-07
- Registry
- NCT06042998
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- RecruitingA Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2023-08
- Registry
- NCT06043466
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou
- RecruitingTo Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
- Phase
- Early phase 1
- Started
- 2023-07
- Registry
- NCT06045091
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2023-10
- Registry
- NCT06049290
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou
- RecruitingSeladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- Phase
- Phase 3
- Started
- 2023-09
- Registry
- NCT06051617
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingNeoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2023-10
- Registry
- NCT06054906
Age 18 years to Not stated (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingPerioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2023-09
- Registry
- NCT06056336
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingElranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- Phase
- Phase 4
- Started
- 2023-10
- Registry
- NCT06057402
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan
- RecruitingStudy on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging
- Phase
- Not given
- Started
- 2023-09
- Registry
- NCT06060769
Age 18 years to Not stated (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingThe Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
- Phase
- N/A
- Started
- 2023-12
- Registry
- NCT06081647
Age 18 years to 60 years (registered criteria)
Led by Renji Hospital; 7 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Nanjing, Shanghai
- RecruitingReduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
- Phase
- Phase 3
- Started
- 2023-10
- Registry
- NCT06092957
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingPulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT06114225
Age 10 years to 65 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingRadiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
- Phase
- Phase 2
- Started
- 2023-01
- Registry
- NCT06121700
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 2/Phase 3
- Started
- 2023-06
- Registry
- NCT06125327
Age 40 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingClinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2023-11
- Registry
- NCT06126406
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhu
- RecruitingA Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-11
- Registry
- NCT06131840
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingClinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
- Phase
- Phase 1
- Started
- 2023-08
- Registry
- NCT06135922
Age 1 year to 60 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingStudy to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
- Phase
- Phase 2
- Started
- 2023-10
- Registry
- NCT06140966
Age 18 years to 70 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- Phase
- Phase 3
- Started
- 2023-11
- Registry
- NCT06145893
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou
- RecruitingPerioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 2
- Started
- 2023-11
- Registry
- NCT06155383
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Jinan, Kunming, Xiamen, Zhengzhou
- RecruitingPrediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
- Phase
- Not given
- Started
- 2023-11
- Registry
- NCT06157060
Age 18 years to 75 years (registered criteria)
Led by Zhujiang Hospital; 3 listed hospitals as study sitesGuangzhou
- RecruitingDVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
- Phase
- Phase 2
- Started
- 2023-12
- Registry
- NCT06158269
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingAll-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
- Phase
- Phase 2
- Started
- 2023-11
- Registry
- NCT06158412
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingA Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
- Phase
- N/A
- Started
- 2023-11
- Registry
- NCT06158919
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Recruiting3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer
- Phase
- Phase 3
- Started
- 2023-01
- Registry
- NCT06161207
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingA Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I
- Phase
- N/A
- Started
- 2023-11
- Registry
- NCT06162338
Age 18 years to 60 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingInfusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
- Phase
- Phase 3
- Started
- 2023-07
- Registry
- NCT06172205
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingImmunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2023-01
- Registry
- NCT06173986
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingM108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2023-12
- Registry
- NCT06177041
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingTislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
- Phase
- Phase 3
- Started
- 2023-12
- Registry
- NCT06177301
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingOriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
- Phase
- Phase 1/Phase 2
- Started
- 2023-10
- Registry
- NCT06182696
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Nanjing, Shanghai, Wuhan
- RecruitingHAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2023-12
- Registry
- NCT06187961
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
- Phase
- Phase 2
- Started
- 2023-10
- Registry
- NCT06190639
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingDEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
- Phase
- N/A
- Started
- 2023-12
- Registry
- NCT06190665
Age 18 years to 80 years (registered criteria)
Led by Zhongda Hospital, Southeast University; 1 listed hospital as study siteBeijing, Nanjing
- RecruitingSafety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
- Phase
- Phase 1/Phase 2
- Started
- 2023-12
- Registry
- NCT06196255
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou
- RecruitingClinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
- Phase
- Phase 2
- Started
- 2023-11
- Registry
- NCT06199895
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingFOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
- Phase
- Phase 3
- Started
- 2023-12
- Registry
- NCT06201065
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingAtrophic Gastritis Predicts the Risk of Gastric Cancer
- Phase
- Not given
- Started
- 2023-12
- Registry
- NCT06203327
Age 18 years to 70 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingApplication of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection
- Phase
- N/A
- Started
- 2023-12
- Registry
- NCT06219096
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingMitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2023-11
- Registry
- NCT06246162
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Nantong UniversityNantong
- RecruitingDara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
- Phase
- Not given
- Started
- 2023-06
- Registry
- NCT06252792
Age 18 years to Not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingRituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
- Phase
- Phase 2
- Started
- 2023-02
- Registry
- NCT06254560
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingAn Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease
- Phase
- Early phase 1
- Started
- 2023-03
- Registry
- NCT06272149
Age 0 months to 24 months (registered criteria)
Led by Xinhua HospitalShanghai
- RecruitingA Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
- Phase
- N/A
- Started
- 2023-01
- Registry
- NCT06277024
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingXerostomia-optimised IMRT Versus Standard IMRT in NPC
- Phase
- N/A
- Started
- 2023-10
- Registry
- NCT06282497
Age 18 years to 70 years (registered criteria)
Led by Zhongshan City People's HospitalZhongshan
- RecruitingBlinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
- Phase
- Phase 4
- Started
- 2023-09
- Registry
- NCT06339775
Age Not stated to 65 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingSerplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
- Phase
- Phase 2
- Started
- 2023-12
- Registry
- NCT06354218
Age 75 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingStudy on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma
- Phase
- Early phase 1
- Started
- 2023-09
- Registry
- NCT06383520
Age 18 years to 65 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingNimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT06410651
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingExploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
- Phase
- Not given
- Started
- 2023-08
- Registry
- NCT06413212
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingNimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT06429839
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Recruitinga Single-arm, Single-center, Open Clinical Study
- Phase
- Not given
- Started
- 2023-07
- Registry
- NCT06431100
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingNeoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
- Phase
- Phase 2
- Started
- 2023-05
- Registry
- NCT06451211
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingPrimary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
- Phase
- Not given
- Started
- 2023-12
- Registry
- NCT06463717
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-04
- Registry
- NCT06508307
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingImage Driven Hepatocellular Carcinoma Invasiveness Evaluation Research
- Phase
- Not given
- Started
- 2023-01
- Registry
- NCT06559761
Age 18 years to 80 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingCT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- Phase
- Phase 1
- Started
- 2023-10
- Registry
- NCT06560827
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2023-09
- Registry
- NCT06678282
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingSurgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2023-11
- Registry
- NCT06688760
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhuhai
- RecruitingA Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
- Phase
- Phase 2
- Started
- 2023-05
- Registry
- NCT06697535
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha
- RecruitingThe Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer
- Phase
- Not given
- Started
- 2023-02
- Registry
- NCT06702683
Age 18 years to Not stated (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- RecruitingNimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT06718205
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingStudy on the Value of Three DWI Scanning Sequences in Staging of Gastric Cancer
- Phase
- N/A
- Started
- 2023-12
- Registry
- NCT06735105
Age 18 years to 80 years (registered criteria)
Led by Yunnan Cancer HospitalKunming
- RecruitingStudy on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
- Phase
- Not given
- Started
- 2023-05
- Registry
- NCT06746701
Age 18 years to 65 years (registered criteria)
Led by Xiangya Hospital; 2 listed hospitals as study sitesChangsha, Guangzhou, Hengyang
- RecruitingLongitudinal Data Registry of Plasma Cell Dyscrasia
- Phase
- Not given
- Started
- 2023-03
- Registry
- NCT06760052
Age 19 years to 99 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
- Phase
- Phase 2
- Started
- 2023-09
- Registry
- NCT06774222
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
- Phase
- N/A
- Started
- 2023-12
- Registry
- NCT06783816
Age not stated (registered criteria)
Led by Shanxi Bethune HospitalTaiyuan
- RecruitingProspective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2023-03
- Registry
- NCT06788353
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingPD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
- Phase
- Phase 2
- Started
- 2023-04
- Registry
- NCT06792162
Age 18 years to Not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingMetastatic Nasopharyngeal Carcinoma
- Phase
- Phase 1
- Started
- 2023-07
- Registry
- NCT06886347
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingEfficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
- Phase
- Phase 2
- Started
- 2023-10
- Registry
- NCT06904014
Age 18 years to 70 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingConstruction of A Multimodal Digital Assessment Model for Myasthenia Gravis
- Phase
- Not given
- Started
- 2023-08
- Registry
- NCT07146425
Age 18 years to Not stated (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingHigh-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
- Phase
- Not given
- Started
- 2023-09
- Registry
- NCT07205523
Age not stated (registered criteria)
Led by Affiliated Hospital of Qinghai UniversityXining
- RecruitingEfficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2023-12
- Registry
- NCT07266493
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingEfficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
- Phase
- Not given
- Started
- 2023-05
- Registry
- NCT07549100
Age 18 years to 75 years (registered criteria)
Led by Shandong Provincial HospitalJinan
- RecruitingAPRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2022-05
- Registry
- NCT04657861
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Recruiting18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2022-01
- Registry
- NCT04813705
Age 18 years to 80 years (registered criteria)
Led by Taizhou HospitalTaizhou
- RecruitingDocetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
- Phase
- Phase 2
- Started
- 2022-01
- Registry
- NCT04840264
Age 18 years to 75 years (registered criteria)
Led by Sixth Affiliated Hospital of Sun Yat-sen University; 1 listed hospital as study siteGuangzhou
- RecruitingNeoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
- Phase
- Phase 2/Phase 3
- Started
- 2022-03
- Registry
- NCT04973306
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingEfficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- Phase
- Phase 2
- Started
- 2022-07
- Registry
- NCT05067348
Age 18 years to 80 years (registered criteria)
Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changsha, Chengdu, Shanghai, Tianjin, Xi'an
- RecruitingClinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
- Phase
- Early phase 1
- Started
- 2022-04
- Registry
- NCT05145361
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Taiyuan, Tianjin, Xi'an
- RecruitingToripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2022-03
- Registry
- NCT05147844
Age 18 years to 75 years (registered criteria)
Led by Xinqiao Hospital, Army Medical UniversityChongqing
- RecruitingA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2022-01
- Registry
- NCT05150691
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
- RecruitingA Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2022-02
- Registry
- NCT05155189
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou, Zhengzhou
- RecruitingA Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
- Phase
- Phase 2
- Started
- 2022-01
- Registry
- NCT05182944
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingA Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Phase
- Phase 4
- Started
- 2022-03
- Registry
- NCT05201781
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingPenpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2022-09
- Registry
- NCT05214222
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- Phase
- Phase 1
- Started
- 2022-03
- Registry
- NCT05219721
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingPhase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Phase
- Phase 3
- Started
- 2022-09
- Registry
- NCT05243797
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou
- RecruitingAnlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
- Phase
- Phase 2
- Started
- 2022-06
- Registry
- NCT05252078
Age 18 years to Not stated (registered criteria)
Led by Jiangxi Cancer HospitalNanchang
- RecruitingA Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
- Phase
- Phase 1
- Started
- 2022-02
- Registry
- NCT05262491
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Jinan, Nanchang, Tianjin
- RecruitingMecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- Phase
- Phase 2
- Started
- 2022-04
- Registry
- NCT05294055
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou
- RecruitingA Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2022-08
- Registry
- NCT05299424
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingStudy Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2022-02
- Registry
- NCT05323201
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou
- RecruitingThe Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma
- Phase
- N/A
- Started
- 2022-01
- Registry
- NCT05323929
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingSurgery or Chemoradiotherapy for Cervical Esophageal Cancer
- Phase
- N/A
- Started
- 2022-04
- Registry
- NCT05327517
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingLong-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)
- Phase
- Not given
- Started
- 2022-05
- Registry
- NCT05332756
Age 2 years to 60 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingA Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
- Phase
- Phase 2
- Started
- 2022-01
- Registry
- NCT05334823
Age 3 years to 21 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou
- RecruitingChemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
- Phase
- Phase 3
- Started
- 2022-04
- Registry
- NCT05340491
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen
- RecruitingMetronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2022-04
- Registry
- NCT05342792
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingDetection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study
- Phase
- Not given
- Started
- 2022-03
- Registry
- NCT05347524
Age 18 years to 74 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingSurgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2022-06
- Registry
- NCT05352321
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou
- RecruitingPD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05357846
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- Phase
- Phase 1
- Started
- 2022-06
- Registry
- NCT05365581
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Wuhan, Zhengzhou
- RecruitingImmune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
- Phase
- Not given
- Started
- 2022-08
- Registry
- NCT05392413
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingEnvafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
- Phase
- Phase 2
- Started
- 2022-06
- Registry
- NCT05397769
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingPrediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
- Phase
- Not given
- Started
- 2022-01
- Registry
- NCT05408897
Age not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2022-08
- Registry
- NCT05409482
Age 18 years to 75 years (registered criteria)
Led by Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou
- RecruitingKN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
- Phase
- Phase 2/Phase 3
- Started
- 2022-04
- Registry
- NCT05427383
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingCT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection
- Phase
- N/A
- Started
- 2022-05
- Registry
- NCT05433467
Age 18 years to Not stated (registered criteria)
Led by Northern Jiangsu People's HospitalYangzhou
- RecruitingValue of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
- Phase
- Not given
- Started
- 2022-07
- Registry
- NCT05443841
Age not stated (registered criteria)
Led by Fudan University Shanghai Cancer Center; 8 listed hospitals as study sitesHefei, Nantong, Shanghai, Shijiazhuang, Taizhou (Jiangsu), Tianjin, Xi'an, Zhengzhou
- RecruitingMicrowave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2022-07
- Registry
- NCT05444478
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha
- RecruitingEpstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
- Phase
- Not given
- Started
- 2022-07
- Registry
- NCT05447169
Age 30 years to 62 years; men only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingOGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
- Phase
- N/A
- Started
- 2022-09
- Registry
- NCT05450835
Age 18 years to 75 years (registered criteria)
Led by Nanfang Hospital; 7 listed hospitals as study sitesChangchun, Changsha, Guangzhou, Shantou, Shenyang
- RecruitingA Study of FVIII Gene Therapy for Hemophilia A
- Phase
- Early phase 1
- Started
- 2022-07
- Registry
- NCT05454774
Age 18 years to Not stated; men only (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingAvapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
- Phase
- Not given
- Started
- 2022-07
- Registry
- NCT05461664
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingA Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
- Phase
- Not given
- Started
- 2022-07
- Registry
- NCT05464875
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingEfficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
- Phase
- N/A
- Started
- 2022-08
- Registry
- NCT05484908
Age 18 years to 65 years (registered criteria)
Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingXELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2022-03
- Registry
- NCT05494060
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingDual-Port Laparoscopic Distal Gastrectomy for Gastric Cancer
- Phase
- N/A
- Started
- 2022-08
- Registry
- NCT05494086
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingAdjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2022-08
- Registry
- NCT05495152
Age 18 years to 70 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingOfatumumab in AQP4-IgG Seropositive NMOSD
- Phase
- Phase 1/Phase 2
- Started
- 2022-06
- Registry
- NCT05504694
Age 18 years to Not stated (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingWatch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
- Phase
- Phase 2
- Started
- 2022-08
- Registry
- NCT05507411
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer Hospital; 2 listed hospitals as study sitesHangzhou, Ningbo
- RecruitingNituzumab (Taixinsheng ®) A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2022-04
- Registry
- NCT05508347
Age 18 years to 70 years (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- RecruitingRadiotherapy Combined With Endostatin and Capecitabine for NPC
- Phase
- Phase 2
- Started
- 2022-08
- Registry
- NCT05514275
Age 18 years to 65 years (registered criteria)
Led by Zhejiang Cancer Hospital; 2 listed hospitals as study sitesHangzhou, Ningbo
- RecruitingInduction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2022-05
- Registry
- NCT05515315
Age 18 years to 70 years (registered criteria)
Led by 900th Hospital of the PLA Joint Logistics Support ForceFuzhou
- RecruitingA Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2022-11
- Registry
- NCT05521802
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingInduction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05527470
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuilin, Wuzhou
- RecruitingThe Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
- Phase
- Phase 2
- Started
- 2022-09
- Registry
- NCT05536102
Age 18 years to 75 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingLaparoscopic vs Open Total Gastrectomy for Gastric Cancer
- Phase
- N/A
- Started
- 2022-10
- Registry
- NCT05537129
Age 20 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Started
- 2022-10
- Registry
- NCT05552222
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingTAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
- Phase
- Phase 1
- Started
- 2022-12
- Registry
- NCT05562024
Age 1 year to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesJinan, Tianjin
- RecruitingConstruction of a Database for TTP
- Phase
- Not given
- Started
- 2022-10
- Registry
- NCT05571774
Age not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingA Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- Phase
- Phase 1/Phase 2
- Started
- 2022-11
- Registry
- NCT05579132
Age 2 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingHuman BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
- Phase
- Phase 2
- Started
- 2022-07
- Registry
- NCT05594797
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Wenzhou
- RecruitingLenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05608213
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- Phase
- Phase 3
- Started
- 2022-12
- Registry
- NCT05611801
Age 1 year to 17 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Wuhan
- RecruitingThe Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
- Phase
- N/A
- Started
- 2022-09
- Registry
- NCT05618041
Age 14 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTaiyuan
- RecruitingClinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer
- Phase
- Phase 2
- Started
- 2022-06
- Registry
- NCT05618821
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingThe Evolution and Prognosis of Moyamoya Disease
- Phase
- Not given
- Started
- 2022-09
- Registry
- NCT05619068
Age 10 years to 60 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingStudy of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2022-11
- Registry
- NCT05620706
Age 40 years to 70 years (registered criteria)
Led by Shenzhen University General HospitalShenzhen
- RecruitingTreatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
- Phase
- N/A
- Started
- 2022-10
- Registry
- NCT05620732
Age 18 years to 75 years (registered criteria)
Led by Shenzhen University General HospitalShenzhen
- RecruitingA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05623020
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
- Phase
- Phase 1/Phase 2
- Started
- 2022-07
- Registry
- NCT05632380
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingSBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
- Phase
- Phase 2
- Started
- 2022-09
- Registry
- NCT05652192
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Registry
- NCT05652920
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Hangzhou, Shanghai
- RecruitingCAV Regimen for R/R Ph- B-ALL
- Phase
- N/A
- Started
- 2022-10
- Registry
- NCT05657652
Age 15 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingClinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase
- Phase
- Not given
- Started
- 2022-12
- Registry
- NCT05661786
Age 18 years to Not stated (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- RecruitingSintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2022-07
- Registry
- NCT05707819
Age 18 years to 70 years (registered criteria)
Led by Guangxi Medical University Cancer HospitalNanning
- RecruitingConcurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2022-12
- Registry
- NCT05717790
Age 18 years to 70 years (registered criteria)
Led by Fourth Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuangzhou, Guilin, Liuzhou, Wuzhou, Zhongshan
- RecruitingIxazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
- Phase
- Phase 4
- Started
- 2022-07
- Registry
- NCT05722405
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingTreatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
- Phase
- N/A
- Started
- 2022-07
- Registry
- NCT05789030
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingLaparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05871099
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- RecruitingGoal-directed LCVP Based on HP in Laparoscopic Hepatectomy
- Phase
- N/A
- Started
- 2022-05
- Registry
- NCT05887661
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingNeoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
- Phase
- Phase 2
- Started
- 2022-08
- Registry
- NCT06006650
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingCD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Started
- 2022-01
- Registry
- NCT06081478
Age 14 years to 85 years (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingLocal Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
- Phase
- Phase 3
- Started
- 2022-09
- Registry
- NCT06190782
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSurgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma.
- Phase
- N/A
- Started
- 2022-11
- Registry
- NCT06529562
Age 18 years to 70 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingFirst-Line and Neoadjuvant Immunotherapy for Gastric Cancer
- Phase
- Not given
- Started
- 2022-01
- Registry
- NCT06727981
Age 18 years to 100 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingRaman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
- Phase
- Not given
- Started
- 2022-09
- Registry
- NCT06822413
Age not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai
- RecruitingEfficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
- Phase
- Phase 2
- Started
- 2022-07
- Registry
- NCT06870942
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingClinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
- Phase
- Not given
- Started
- 2022-07
- Registry
- NCT07064746
Age Not stated to 18 years (registered criteria)
Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing
- RecruitingSapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2022-08
- Registry
- NCT07327216
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang
- RecruitingSerial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
- Phase
- Not given
- Started
- 2022-01
- Registry
- NCT07516678
Age not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingStudy of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
- Phase
- Phase 3
- Started
- 2021-01
- Registry
- NCT04415853
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingEffect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
- Phase
- Phase 3
- Started
- 2021-08
- Registry
- NCT04436965
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy
- Phase
- Phase 3
- Started
- 2021-03
- Registry
- NCT04478292
Age Not stated to 18 years (registered criteria)
Led by Shanghai Children's Medical CenterShanghai
- RecruitingOxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer
- Phase
- Phase 3
- Started
- 2021-01
- Registry
- NCT04483076
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 2
- Started
- 2021-02
- Registry
- NCT04634552
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Suzhou, Tianjin, Xi'an
- RecruitingCD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
- Phase
- Early phase 1
- Started
- 2021-11
- Registry
- NCT04662294
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingMulticenter Study on Laparoscopic Total Gastrectomy for Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2021-01
- Registry
- NCT04710758
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingGene Therapy for Chinese Hemophilia A
- Phase
- N/A
- Started
- 2021-03
- Registry
- NCT04728841
Age 18 years to Not stated; men only (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingNeo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)
- Phase
- N/A
- Started
- 2021-02
- Registry
- NCT04777942
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingToripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2021-03
- Registry
- NCT04778956
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesFoshan, Guangzhou, Zhongshan
- RecruitingTrametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2021-01
- Registry
- NCT04803318
Age 18 years to 85 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingPembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
- Phase
- Phase 3
- Started
- 2021-12
- Registry
- NCT04807673
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingComparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer
- Phase
- Not given
- Started
- 2021-05
- Registry
- NCT04809025
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2021-01
- Registry
- NCT04843215
Age 18 years to 70 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingRelationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.
- Phase
- Not given
- Started
- 2021-05
- Registry
- NCT04850729
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingChina Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine
- Phase
- Not given
- Started
- 2021-03
- Registry
- NCT04885374
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingToripalimab Plus FLOT in Locally Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2021-06
- Registry
- NCT04891016
Age 18 years to 70 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingStudy of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2021-06
- Registry
- NCT04900818
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- RecruitingIntrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma
- Phase
- N/A
- Started
- 2021-05
- Registry
- NCT04903678
Age not stated (registered criteria)
Led by Eye & ENT Hospital of Fudan UniversityShanghai
- RecruitingGene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy
- Phase
- Phase 2/Phase 3
- Started
- 2021-06
- Registry
- NCT04912843
Age 12 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Phase
- Phase 2
- Started
- 2021-08
- Registry
- NCT04924075
Age 12 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingProspective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
- Phase
- Phase 2
- Started
- 2021-09
- Registry
- NCT04933669
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingCamrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2021-06
- Registry
- NCT04944914
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingGenotype-Phenotype Correlations in Patients With Alport Syndrome
- Phase
- Not given
- Started
- 2021-01
- Registry
- NCT04947813
Age not stated (registered criteria)
Led by Xinhua HospitalShanghai
- RecruitingA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Phase
- Phase 3
- Started
- 2021-07
- Registry
- NCT04951622
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an
- RecruitingIntratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2021-03
- Registry
- NCT04952272
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Registry
- NCT04973605
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou
- RecruitingStudy of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
- Phase
- Phase 3
- Started
- 2021-07
- Registry
- NCT04997837
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingGastric Cancer Marker Detection and Its Kit Development
- Phase
- Not given
- Started
- 2021-01
- Registry
- NCT05010863
Age not stated (registered criteria)
Led by Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical UniversityWenzhou
- RecruitingA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Phase
- Phase 3
- Started
- 2021-10
- Registry
- NCT05020236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou
- RecruitingPhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Registry
- NCT05024214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai
- RecruitingPD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer
- Phase
- Phase 2
- Started
- 2021-09
- Registry
- NCT05033392
Age 18 years to 79 years (registered criteria)
Led by Shenzhen People's HospitalShenzhen
- RecruitingThe Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy
- Phase
- Early phase 1
- Started
- 2021-09
- Registry
- NCT05035108
Age 30 years to 80 years (registered criteria)
Led by Sir Run Run Shaw HospitalHangzhou
- RecruitingGPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2021-09
- Registry
- NCT05047510
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesLuzhou, Zhuhai
- RecruitingCryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2021-09
- Registry
- NCT05057845
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2021-09
- Registry
- NCT05062005
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingHepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
- Phase
- Phase 2/Phase 3
- Started
- 2021-06
- Registry
- NCT05062837
Age 18 years to 75 years (registered criteria)
Led by Guangxi Medical University Cancer HospitalNanning
- Recruiting18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
- Phase
- Early phase 1
- Started
- 2021-09
- Registry
- NCT05069220
Age 1 year to 80 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingHigh Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
- Phase
- Not given
- Started
- 2021-10
- Registry
- NCT05072626
Age Not stated to 3 months (registered criteria)
Led by Children's Hospital of Fudan UniversityShanghai
- RecruitingRuxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
- Phase
- Phase 2
- Started
- 2021-12
- Registry
- NCT05088226
Age 12 years to 65 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingImmune Score Based Radiomics in Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2021-11
- Registry
- NCT05126160
Age 18 years to 70 years (registered criteria)
Led by Zhejiang Cancer Hospital; 4 listed hospitals as study sitesHangzhou, Ningbo, Wenzhou, Wuhan
- RecruitingOpen-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Phase
- Phase 3
- Started
- 2021-11
- Registry
- NCT05145127
Age 1 year to 74 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Nanchang, Tianjin, Wuhan
- RecruitingTriplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Registry
- NCT05187338
Age 18 years to 70 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
- Phase
- Phase 1
- Started
- 2021-11
- Registry
- NCT05194982
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chongqing, Guangzhou, Wuhan
- RecruitingA Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
- Phase
- Not given
- Started
- 2021-07
- Registry
- NCT05283993
Age not stated (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingAntiviral Therapy for Patients With Liver Cancer After Surgery
- Phase
- Not given
- Started
- 2021-12
- Registry
- NCT05466565
Age 18 years to 65 years (registered criteria)
Led by Xiangya HospitalChangsha
- RecruitingMulti-parametric MRI and Dual-energy CT in Patients of Gastric Cancer
- Phase
- Not given
- Started
- 2021-11
- Registry
- NCT05508126
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingProximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer
- Phase
- N/A
- Started
- 2021-01
- Registry
- NCT05514769
Age 18 years to 85 years (registered criteria)
Led by Nanchong Central HospitalNanchong
- RecruitingComparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC
- Phase
- N/A
- Started
- 2021-06
- Registry
- NCT05775419
Age 18 years to 70 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingDevelopment of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms
- Phase
- Not given
- Started
- 2021-06
- Registry
- NCT06078930
Age 18 years to 90 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingIndividualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
- Phase
- Not given
- Started
- 2021-09
- Registry
- NCT06099912
Age 65 years to Not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingHAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2021-01
- Registry
- NCT06333561
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingAn Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2021-03
- Registry
- NCT07080437
Age 70 years to Not stated (registered criteria)
Led by Chongqing University Three Gorges HospitalChongqing
- RecruitingA Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents
- Phase
- Phase 2
- Started
- 2021-06
- Registry
- NCT07300449
Age Not stated to 18 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingCarilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2021-03
- Registry
- NCT07320586
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingPD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
- Phase
- Phase 3
- Started
- 2020-03
- Registry
- NCT03907826
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen
- RecruitingSamples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT03972956
Age 18 years to 80 years (registered criteria)
Led by Renmin Hospital of Wuhan UniversityWuhan
- RecruitingScreening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City
- Phase
- Not given
- Started
- 2020-04
- Registry
- NCT04085900
Age 30 years to 69 years (registered criteria)
Led by Zhongshan City People's Hospital; 1 listed hospital as study siteWuzhou, Zhongshan
- RecruitingRFA Plus Carrizumab vs Carrizumab Alone for HCC
- Phase
- Phase 2
- Started
- 2020-08
- Registry
- NCT04150744
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
- Phase
- Early phase 1
- Started
- 2020-01
- Registry
- NCT04227015
Age 3 years to 70 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingNeo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
- Phase
- Phase 3
- Started
- 2020-04
- Registry
- NCT04280822
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingReduced Port Laparoscopic Gastrectomy for Gastric Cancer
- Phase
- N/A
- Started
- 2020-03
- Registry
- NCT04295473
Age 18 years to 90 years (registered criteria)
Led by Nanchong Central HospitalNanchong
- RecruitingA Pilot Study in Severe Patients With Takayasu Arteritis.
- Phase
- Phase 4
- Started
- 2020-03
- Registry
- NCT04300686
Age 14 years to 100 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingToripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2020-06
- Registry
- NCT04376866
Age 18 years to 65 years (registered criteria)
Led by Guangxi Medical University Cancer HospitalNanning
- RecruitingPlasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2020-06
- Registry
- NCT04425265
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhuhai
- RecruitingNedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2020-08
- Registry
- NCT04437329
Age 18 years to 65 years (registered criteria)
Led by Affiliated Cancer Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingReduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2020-08
- Registry
- NCT04448522
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan
- RecruitingToripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2020-07
- Registry
- NCT04453813
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan, Zhuhai
- RecruitingConcurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2020-09
- Registry
- NCT04453826
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan, Zhuhai
- RecruitingValue of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
- Phase
- Early phase 1
- Started
- 2020-08
- Registry
- NCT04504526
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- RecruitingPhase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
- Phase
- N/A
- Started
- 2020-01
- Registry
- NCT04519905
Age 76 years to Not stated (registered criteria)
Led by Huadong Hospital, Fudan University; 1 listed hospital as study siteNanjing, Shanghai
- RecruitingDetecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
- Phase
- Not given
- Started
- 2020-04
- Registry
- NCT04544969
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTo Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2020-06
- Registry
- NCT04547673
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen University; 1 listed hospital as study siteGuangzhou
- RecruitingSafety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
- Phase
- Early phase 1
- Started
- 2020-09
- Registry
- NCT04561557
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingTislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
- Phase
- Phase 2
- Started
- 2020-12
- Registry
- NCT04615143
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingNational Longitudinal Cohort of Hematological Diseases
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT04645199
Age not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingClinical Research of Tapering UDCA in PBC Patients With a Complete Response
- Phase
- Phase 4
- Started
- 2020-01
- Registry
- NCT04650243
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingAjuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
- Phase
- N/A
- Started
- 2020-07
- Registry
- NCT04688801
Age 25 years to 80 years (registered criteria)
Led by Second Hospital of Shandong UniversityJinan
- RecruitingIntra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
- Phase
- Phase 2
- Started
- 2020-11
- Registry
- NCT04770207
Age 18 years to 99 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingPhase Ib Clinical Study of Keynatinib
- Phase
- Phase 1
- Started
- 2020-09
- Registry
- NCT04807881
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Shanghai
- RecruitingThe Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT04858724
Age not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingAdjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
- Phase
- Phase 3
- Started
- 2020-11
- Registry
- NCT05080010
Age not stated (registered criteria)
Led by Zhongshan Ophthalmic CenterGuangzhou
- RecruitingPrediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2020-09
- Registry
- NCT05140746
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingCorrelation of Microbiome and Metabonomics With IgA Nephropathy
- Phase
- Not given
- Started
- 2020-05
- Registry
- NCT05190848
Age 16 years to 65 years (registered criteria)
Led by Guangdong Provincial People's Hospital; 4 listed hospitals as study sitesGuangzhou
- RecruitingAutoInflammatory Disease Alliance Registry (AIDA)
- Phase
- Not given
- Started
- 2020-08
- Registry
- NCT05200715
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Chongqing
- RecruitingLinear Stapler Versus Circular Stapler in Esophagojejunostomy
- Phase
- N/A
- Started
- 2020-01
- Registry
- NCT05360069
Age 18 years to 90 years (registered criteria)
Led by Nanchong Central HospitalNanchong
- RecruitingAmbispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
- Phase
- Not given
- Started
- 2020-05
- Registry
- NCT05520788
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingCombined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2020-05
- Registry
- NCT05713994
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Fujian Medical UniversityQuanzhou
- RecruitingNeoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT05740995
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingSafety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
- Phase
- Early phase 1
- Started
- 2020-12
- Registry
- NCT05745532
Age 8 years to 16 years (registered criteria)
Led by Shenzhen Children's HospitalShenzhen
- RecruitingSurveillance and Tracking the Outcomes of Chronic Latent EBV Infection
- Phase
- Not given
- Started
- 2019-07
- Registry
- NCT03491605
Age not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingS-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)
- Phase
- Phase 3
- Started
- 2019-01
- Registry
- NCT03941561
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHefei, Nanchang, Wuhu
- RecruitingInfusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2019-01
- Registry
- NCT03949231
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingNeoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2019-04
- Registry
- NCT03964753
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingA Registered Cohort Study on Amyotrophic Lateral Sclerosis
- Phase
- Not given
- Started
- 2019-07
- Registry
- NCT04008329
Age not stated (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- RecruitingA Registered Cohort Study on SMA
- Phase
- Not given
- Started
- 2019-07
- Registry
- NCT04010604
Age 1 week to 70 years (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- RecruitingA Registered Cohort Study on Wilson's Disease
- Phase
- Not given
- Started
- 2019-07
- Registry
- NCT04012658
Age not stated (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- RecruitingA Registered Cohort Study on Duchenne Muscular Dystrophy
- Phase
- Not given
- Started
- 2019-07
- Registry
- NCT04012671
Age 2 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- RecruitingComparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
- Phase
- Phase 1/Phase 2
- Started
- 2019-07
- Registry
- NCT04025450
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingPaclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
- Phase
- N/A
- Started
- 2019-09
- Registry
- NCT04047953
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingClinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
- Phase
- Not given
- Started
- 2019-01
- Registry
- NCT04106830
Age 16 years to 75 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingComparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2019-09
- Registry
- NCT04135664
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest Hospital; 5 listed hospitals as study sitesNanchang, Shanghai, Tianjin
- RecruitingNeoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
- Phase
- Phase 3
- Started
- 2019-10
- Registry
- NCT04138212
Age 18 years to 70 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingStudy of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- Phase
- Phase 2
- Started
- 2019-11
- Registry
- NCT04143724
Age 6 years to 17 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Guangzhou, Nanning, Shenzhen
- RecruitingBCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
- Phase
- Phase 1
- Started
- 2019-07
- Registry
- NCT04162353
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingStudy on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma
- Phase
- N/A
- Started
- 2019-12
- Registry
- NCT04174079
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
- Phase
- Not given
- Started
- 2019-11
- Registry
- NCT04182984
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingChemoradiotherapy in Unresectable Esophageal Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2019-10
- Registry
- NCT04278287
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 4 listed hospitals as study sitesAnyang, Beijing, Changsha, Nanjing
- RecruitingTo Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2019-12
- Registry
- NCT04365751
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingNatural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
- Phase
- Not given
- Started
- 2019-11
- Registry
- NCT04454892
Age not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingLiver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2019-01
- Registry
- NCT07782632
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingA Study of HQP1351 in Patients With GIST or Other Solid Tumors
- Phase
- Phase 1
- Started
- 2018-07
- Registry
- NCT03594422
Age 12 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou
- RecruitingThe Overall Survival of Patients With Unresectable HCC in Real-life
- Phase
- Not given
- Started
- 2018-07
- Registry
- NCT03612726
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingComparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site
- Phase
- Not given
- Started
- 2018-10
- Registry
- NCT03716089
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingTrans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
- Phase
- Phase 2/Phase 3
- Started
- 2018-11
- Registry
- NCT03755739
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingCisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2018-01
- Registry
- NCT03919552
Age 18 years to 64 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingRegional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
- Phase
- Not given
- Started
- 2018-06
- Registry
- NCT06876753
Age 18 years to 80 years (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- RecruitingGPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
- Phase
- Phase 1
- Started
- 2017-07
- Registry
- NCT03198546
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical University; 1 listed hospital as study siteGuangzhou
- RecruitingApatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
- Phase
- Phase 2
- Started
- 2017-09
- Registry
- NCT03219593
Age 65 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Bengbu Medical UniversityBengbu
- RecruitingEndoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
- Phase
- N/A
- Started
- 2017-10
- Registry
- NCT03353467
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFoshan, Guangzhou, Nanning, Zhongshan
- RecruitingFenofibrate in Patients With Primary Biliary Cholangitis (PBC)
- Phase
- Phase 2/Phase 3
- Started
- 2017-04
- Registry
- NCT06365424
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingIgA Nephropathy Biomarkers Evaluation Study (INTEREST)
- Phase
- Not given
- Started
- 2016-11
- Registry
- NCT02954419
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingChemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer
- Phase
- N/A
- Started
- 2016-11
- Registry
- NCT02972372
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Henan University of Science and Technology; 1 listed hospital as study siteAnyang, Luoyang
- RecruitingNational Registry of IgG4-RD in China
- Phase
- Not given
- Started
- 2016-12
- Registry
- NCT03023371
Age not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingStudy of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2016-09
- Registry
- NCT03196414
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingA Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA)
- Phase
- Not given
- Started
- 2016-01
- Registry
- NCT03372980
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingClinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement
- Phase
- Not given
- Started
- 2016-01
- Registry
- NCT07184814
Age 18 years to Not stated (registered criteria)
Led by China-Japan Friendship HospitalBeijing
- RecruitingChina Registry for Genetic / Metabolic Liver Diseases
- Phase
- Not given
- Started
- 2015-06
- Registry
- NCT03131427
Age not stated (registered criteria)
Led by Beijing Friendship Hospital; 1 listed hospital as study siteBeijing
- RecruitingTreatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
- Phase
- Not given
- Started
- 2014-01
- Registry
- NCT05388682
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPredicting Gastric Cancer Response to Chemo With Multimodal AI Model
- Phase
- Not given
- Started
- 2013-02
- Registry
- NCT06451393
Age 20 years to 90 years (registered criteria)
Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingA Prospective Cohort Study of IgG4RD in China
- Phase
- Not given
- Started
- 2012-01
- Registry
- NCT01670695
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingIgA Nephropathy Registration Initiative of High Quality (INSIGHT)
- Phase
- Not given
- Started
- 2012-11
- Registry
- NCT03001947
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingInfluence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer
- Phase
- Not given
- Started
- 2012-01
- Registry
- NCT04522687
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingRegistry of Multicenter Brain-Heart Comorbidity in China
- Phase
- Not given
- Started
- 2012-01
- Registry
- NCT05961748
Age 18 years to Not stated (registered criteria)
Led by Beijing Tiantan Hospital; 4 listed hospitals as study sitesBeijing, Harbin, Shanghai, Zhengzhou
- RecruitingPrecision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques
- Phase
- Not given
- Started
- 2010-01
- Registry
- NCT07336394
Age not stated (registered criteria)
Led by Fuwai HospitalBeijing
- RecruitingCombination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
- Phase
- Phase 2/Phase 3
- Started
- 2009-12
- Registry
- NCT02851784
Age not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingRole for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease
- Phase
- Not given
- Started
- 2004-01
- Registry
- NCT04965545
Age 6 years to 65 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingClinical Features and Outcome in Patients With Osseomuscular Type of Wilson's Disease
- Phase
- Not given
- Started
- 2004-01
- Registry
- NCT04965558
Age 6 years to 65 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingNK521 in the Treatment of Advanced Solid Tumors
- Phase
- Early phase 1
- Started
- 2027-01
- Registry
- NCT07657416
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei
- Not yet recruitingShuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
- Phase
- Phase 2
- Started
- 2027-09
- Registry
- NCT07691645
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingStudy of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 2
- Started
- 2027-12
- Registry
- NCT07695740
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingConditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT
- Phase
- Phase 2
- Started
- 2027-08
- Registry
- NCT07885982
Age 1 year to 50 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- Not yet recruitingIntegration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.
- Phase
- Not given
- Started
- 2027-01
- Registry
- NCT07912853
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingSintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT06365008
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingNeoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2026-02
- Registry
- NCT06952621
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- Not yet recruitingIvonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07064902
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesGuangzhou, Guilin, Xiamen
- Not yet recruitingStudy to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07222553
Age 2 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Changsha
- Not yet recruitingRisk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07268690
Age 18 years to 70 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- Not yet recruitingA Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis
- Phase
- N/A
- Started
- 2026-03
- Registry
- NCT07298928
Age Not stated to 18 years (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- Not yet recruitingBecotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07303283
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Guangxi Medical UniversityNanning
- Not yet recruitingEsomeprazole Plus Sucralfate for Post-ESD Ulcer Healing
- Phase
- Phase 4
- Started
- 2026-04
- Registry
- NCT07312370
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteLanzhou
- Not yet recruitingClinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
- Phase
- Phase 3
- Started
- 2026-12
- Registry
- NCT07314203
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Not yet recruitingFAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07314372
Age 18 years to Not stated (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- Not yet recruitingRecurrence After Gastric and Intestinal Polyp Resection
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07314554
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteLanzhou
- Not yet recruitingQL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07315035
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingIvarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07324473
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Chongqing Medical UniversityChongqing
- Not yet recruitingExploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07328802
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingRobotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer
- Phase
- Phase 3
- Started
- 2026-02
- Registry
- NCT07331454
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingTongji NADs Cohort
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07333196
Age 18 years to 80 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingA Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07333573
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingIsa-VRD in TIE HRMM
- Phase
- Phase 4
- Started
- 2026-01
- Registry
- NCT07334535
Age 18 years to 80 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingA Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer
- Phase
- N/A
- Started
- 2026-01
- Registry
- NCT07337031
Age 18 years to 75 years (registered criteria)
Led by Eastern Hepatobiliary Surgery HospitalShanghai
- Not yet recruitingHead to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma
- Phase
- Early phase 1
- Started
- 2026-01
- Registry
- NCT07352345
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingApplication Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma
- Phase
- N/A
- Started
- 2026-02
- Registry
- NCT07353554
Age 18 years to 85 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingNanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07356037
Age 18 years to 85 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- Not yet recruitingIBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07361991
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingDrug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07363356
Age 18 years to 70 years (registered criteria)
Led by Eastern Hepatobiliary Surgery HospitalShanghai
- Not yet recruitingA Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-01
- Registry
- NCT07368023
Age 16 years to Not stated (registered criteria)
Led by Ningbo Medical Center Lihuili HospitalNingbo
- Not yet recruitingPerioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07374250
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingA Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- Phase
- N/A
- Started
- 2026-02
- Registry
- NCT07376720
Age 18 years to 78 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingIndocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07376876
Age 18 years to 80 years (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- Not yet recruitingScipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07388758
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingMegestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07391826
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingUniversal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/ BCMA(QT-019C) in Patients With r/ r Neurological Autoimmune Diseases
- Phase
- Early phase 1
- Started
- 2026-03
- Registry
- NCT07392528
Age 18 years to Not stated (registered criteria)
Led by Tianjin Huanhu HospitalTianjin
- Not yet recruitingA Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
- Phase
- Phase 2/Phase 3
- Started
- 2026-03
- Registry
- NCT07392866
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- Not yet recruitingClinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
- Phase
- Early phase 1
- Started
- 2026-09
- Registry
- NCT07394205
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- Not yet recruitingA Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
- Phase
- Early phase 1
- Started
- 2026-01
- Registry
- NCT07399444
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 4 listed hospitals as study sitesNanchang, Tianjin, Wuhan, Xuzhou, Zhengzhou
- Not yet recruitingShort-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07403435
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingA Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07446335
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingLDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07453875
Age 18 years to 75 years (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- Not yet recruitingSafety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
- Phase
- N/A
- Started
- 2026-04
- Registry
- NCT07480382
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingEvaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07486310
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingSafety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
- Phase
- Early phase 1
- Started
- 2026-03
- Registry
- NCT07487402
Age 19 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingClinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07491263
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- Not yet recruitingClinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07493993
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingComparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07507071
Age 18 years to 75 years (registered criteria)
Led by Changhai HospitalShanghai
- Not yet recruitingA Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07507526
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingFeasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07508956
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruiting18F-FAPI PET/CT and MRI in Gastric Cancer
- Phase
- Not given
- Started
- 2026-05
- Registry
- NCT07510867
Age 20 years to 80 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingU96-CAR-T-Cells For R/R B-ALL
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07511426
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingBeta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07511894
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- Not yet recruitingSHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07524374
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingProspective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07531979
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingBenmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07537777
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- Not yet recruitingLocal Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07537946
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingSurgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
- Phase
- N/A
- Started
- 2026-04
- Registry
- NCT07537959
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingDenosumab Strategy for Liver Cancer With Bone Metastases
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07537972
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingA Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
- Phase
- Early phase 1
- Started
- 2026-04
- Registry
- NCT07539233
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingEvaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
- Phase
- Phase 1
- Started
- 2026-04
- Registry
- NCT07539610
Age 18 years to 69 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingGAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07540390
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingClinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
- Phase
- N/A
- Started
- 2026-05
- Registry
- NCT07552506
Age 14 years to 50 years; women only (registered criteria)
Led by Union Hospital; 3 listed hospitals as study sitesHangzhou, Wuhan, Zhengzhou
- Not yet recruitingEfficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection
- Phase
- Early phase 1
- Started
- 2026-03
- Registry
- NCT07553767
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNingbo
- Not yet recruitingNon-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
- Phase
- Not given
- Started
- 2026-04
- Registry
- NCT07554742
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingEfficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
- Phase
- Phase 1
- Started
- 2026-12
- Registry
- NCT07556120
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei
- Not yet recruitingEpalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07557914
Age 18 years to 80 years (registered criteria)
Led by First Hospital of China Medical UniversityShenyang
- Not yet recruitingPhase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07558200
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingStomach-Partitioning Versus Conventional Gastrojejunostomy for Malignant Gastric Outlet Obstruction: A Multicenter Randomized Controlled Trial
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07561073
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanning
- Not yet recruitingNanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07565415
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- Not yet recruitingClinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07569757
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou
- Not yet recruitingYMN-A02 for Advanced Primary Hepatocellular Carcinoma.
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07580261
Age 18 years to 70 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingHybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions
- Phase
- Not given
- Started
- 2026-04
- Registry
- NCT07582419
Age 18 years to 85 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- Not yet recruitingA Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07583316
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingThe Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
- Phase
- Early phase 1
- Started
- 2026-05
- Registry
- NCT07592754
Age 18 years to 65 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingA Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07593911
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- Not yet recruitingMultimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07596134
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Nanchang, Taizhou
- Not yet recruitingAdaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2/Phase 3
- Started
- 2026-06
- Registry
- NCT07603349
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- Not yet recruitingRetlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07610629
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Not yet recruitingA Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer
- Phase
- N/A
- Started
- 2026-05
- Registry
- NCT07615907
Age 18 years to 80 years (registered criteria)
Led by Jinling HospitalNanjing
- Not yet recruitingRetlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07618910
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- Not yet recruitingTafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07621562
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingA Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07623642
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin
- Not yet recruitingSafety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2026-07
- Registry
- NCT07628595
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingPhase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Registry
- NCT07641140
Age 18 years to 60 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- Not yet recruitingMannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07655661
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingNon-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers
- Phase
- Not given
- Started
- 2026-06
- Registry
- NCT07656740
Age not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingYttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07657273
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingOne-Click Autofocus Versus Segmented Focus in Gastric Endoscopy
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07664813
Age 18 years to Not stated (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- Not yet recruitingA Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07669740
Age 15 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07676266
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- Not yet recruitingNeoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07678580
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- Not yet recruitingA Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07682272
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Study of Combination Therapy in Patients With Resectable Liver Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07684040
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang
- Not yet recruitingZanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07685704
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- Not yet recruitingSonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
- Phase
- Phase 1/Phase 2
- Started
- 2026-08
- Registry
- NCT07687004
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingA Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07688291
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- Not yet recruitingA Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2026-11
- Registry
- NCT07691762
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- Not yet recruitingClinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
- Phase
- Early phase 1
- Started
- 2026-08
- Registry
- NCT07696481
Age 3 years to 75 years (registered criteria)
Led by Zhujiang HospitalGuangzhou
- Not yet recruitingBecotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07697040
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingCrisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
- Phase
- Phase 4
- Started
- 2026-06
- Registry
- NCT07699770
Age 18 years to 75 years (registered criteria)
Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changchun, Chongqing, Kunming, Shenyang, Xi'an
- Not yet recruitingSacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07701681
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen
- Phase
- Phase 4
- Started
- 2026-07
- Registry
- NCT07709884
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingUniversal STAR-T Cell Injection in Generalized Myasthenia Gravis
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07714798
Age 18 years to 65 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingEfficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
- Phase
- Phase 3
- Started
- 2026-08
- Registry
- NCT07719543
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingEarly Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07721103
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingThe Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07724951
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai
- Not yet recruitingA Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07726160
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingAI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07729618
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingAI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07732504
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingProspective Assessment of Alignment Between Multimodal Artificial Intelligence and Multidisciplinary Team Decisions in Gastrointestinal Oncology
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07746830
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingSHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07749859
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingRadscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07756190
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingEvaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Registry
- NCT07761286
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHarbin
- Not yet recruitingEvaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.
- Phase
- N/A
- Started
- 2026-07
- Registry
- NCT07762547
Age 18 years to 70 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- Not yet recruitingHome-based Whole Course Multimodal Prehabilitation Based on 5G + Artificial Intelligence Mobile Health
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07764523
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- Not yet recruitingA Open-Label Phase in Participants With Multiple Myeloma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07764861
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingImpacted Tooth Management and Osteoradionecrosis Risk in NPC
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07764887
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuilin, Liuzhou, Nanning, Wuzhou, Zhongshan
- Not yet recruitingPragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07768085
Age 18 years to Not stated (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- Not yet recruitingStandardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07769658
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou University; 5 listed hospitals as study sitesChengdu, Guangzhou, Kunming, Shanghai, Tianjin, Zhengzhou
- Not yet recruitingRetlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC
- Phase
- N/A
- Started
- 2026-09
- Registry
- NCT07769866
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingAn Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07770672
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingHCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07780357
Age 18 years to Not stated (registered criteria)
Led by Beijing Friendship HospitalBeijing
- Not yet recruitingStudy of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07780721
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Putian UniversityPutian
- Not yet recruitingAI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07782294
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesAnyang, Hangzhou, Shanghai
- Not yet recruitingA Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07783321
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingA Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07784413
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingA Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer
- Phase
- Phase 3
- Started
- 2026-10
- Registry
- NCT07788001
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Not yet recruitingA Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion
- Phase
- Phase 4
- Started
- 2026-08
- Registry
- NCT07790419
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingHigh-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07791979
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingTR115 in ARID1A-Mutated Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07793318
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingPlatinum-Free Regimen in Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07794488
Age 18 years to 70 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingA Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07797881
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingPaclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07799077
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07799649
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingNebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
- Phase
- Early phase 1
- Started
- 2026-10
- Registry
- NCT07806045
Age 18 years to 80 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingEfficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07809724
Age 18 years to 74 years (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingHP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07811986
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07813572
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- Not yet recruitingAn Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
- Phase
- Phase 1
- Started
- 2026-09
- Registry
- NCT07818291
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai
- Not yet recruitingA Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Registry
- NCT07818486
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChongqing, Guangzhou
- Not yet recruitingRisk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07822906
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingNeoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07823270
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingJS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
- Phase
- Phase 3
- Started
- 2026-10
- Registry
- NCT07823348
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shanghai
- Not yet recruitingHeterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07824765
Age 18 years to Not stated (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- Not yet recruitingLocal Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07824856
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingSafety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07828899
Age 18 years to 85 years (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical University; 2 listed hospitals as study sitesJinan, Shijiazhuang, Wenzhou
- Not yet recruitingSNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
- Phase
- Early phase 1
- Started
- 2026-09
- Registry
- NCT07830238
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
- Not yet recruitingCM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07830485
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingTACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07836309
Age 16 years to Not stated (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- Not yet recruitingImmunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07840976
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingFecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07847671
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingPhase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
- Phase
- Phase 1
- Started
- 2026-11
- Registry
- NCT07861425
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- Not yet recruitingSurgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2026-12
- Registry
- NCT07866612
Age 18 years to 80 years (registered criteria)
Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
- Not yet recruitingLenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II Study
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07870772
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingExploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07872696
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingA Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction Cancer
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07878221
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingTripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07878585
Age 45 years to 79 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingMultimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07880106
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingSBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07882056
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingLymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07902596
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province Hospital; 6 listed hospitals as study sitesNanjing, Qingdao, Shanghai, Shijiazhuang, Suzhou
- Not yet recruitingBecotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-11
- Registry
- NCT07902713
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingQLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- Phase
- Phase 2
- Started
- 2026-12
- Registry
- NCT07903636
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingSND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2026-12
- Registry
- NCT07903857
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- Not yet recruitingEffect of High-flow Nasal Cannula Oxygenation on the Incidence of Hypoxemia During Painless Gastrointestinal Endoscopy in Patients at High Risk for Obstructive Sleep Apnea Syndrome in High-altitude Regions
- Phase
- N/A
- Started
- 2026-11
- Registry
- NCT07904260
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- Not yet recruitingStudy of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-12
- Registry
- NCT07910903
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingD2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-11
- Registry
- NCT07912606
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingNeoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
- Phase
- Phase 2
- Started
- 2026-11
- Registry
- NCT07912957
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingMulti-center Prospective Validation of Real-Time AI-EGGIM System
- Phase
- Not given
- Started
- 2026-11
- Registry
- NCT07915843
Age not stated (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- Not yet recruitingA Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
- Phase
- Early phase 1
- Started
- 2026-12
- Registry
- NCT07917923
Age 18 years to 65 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingDevelopment and Validation of a Biopsy Decision Model for Nasopharyngeal Carcinoma Based on Serological Markers and Endoscopic Features
- Phase
- Not given
- Started
- 2026-11
- Registry
- NCT07918755
Age 18 years to Not stated (registered criteria)
Led by Zhongshan City People's Hospital; 1 listed hospital as study siteNanning, Zhongshan
- Not yet recruitingBusulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
- Phase
- N/A
- Started
- 2026-11
- Registry
- NCT07919470
Age 14 years to 65 years (registered criteria)
Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing, Langfang
- Not yet recruitingNIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
- Phase
- Phase 2
- Started
- 2026-11
- Registry
- NCT07919717
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingGK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
- Phase
- Phase 1
- Started
- 2026-11
- Registry
- NCT07923396
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingProspective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2025-12
- Registry
- NCT05912582
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Cancer HospitalNanjing
- Not yet recruitingFOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Registry
- NCT06409637
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingA Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer
- Phase
- Not given
- Started
- 2025-04
- Registry
- NCT06464601
Age 18 years to 75 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- Not yet recruitingUniversal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
- Phase
- Early phase 1
- Started
- 2025-02
- Registry
- NCT06485232
Age 18 years to 75 years (registered criteria)
Led by Xuanwu HospitalBeijing
- Not yet recruitingAspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
- Phase
- Phase 3
- Started
- 2025-09
- Registry
- NCT06580223
Age 18 years to 90 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingGP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06605131
Age 6 years to 18 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingLiver Cancer Prognosis Investigation Study
- Phase
- Not given
- Started
- 2025-04
- Registry
- NCT06623734
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingCombination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06708650
Age 18 years to 75 years (registered criteria)
Led by Guiping People's HospitalGuigang
- Not yet recruitingSBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Registry
- NCT06739317
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- Not yet recruitingPreliminary Efficacy Analysis of "C" Single Flap Plasty Reconstruction After Laparoscopic Proximal Gastrectomy
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06741501
Age 18 years to 80 years (registered criteria)
Led by Northern Jiangsu People's HospitalYangzhou
- Not yet recruitingEffect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06749678
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingEndoscopic Cryoablation Combined With PD-1 in Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06759233
Age 18 years to 80 years (registered criteria)
Led by Huashan HospitalShanghai
- Not yet recruitingAn Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06759948
Age 18 years to 75 years (registered criteria)
Led by Huashan HospitalShanghai
- Not yet recruitingA Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2025-01
- Registry
- NCT06779461
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBengbu, Guangzhou, Lanzhou, Nanjing, Shanghai, Tianjin, Zhengzhou
- Not yet recruitingStudy of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Registry
- NCT06791824
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingFusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field for Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT06798194
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingA Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Registry
- NCT06799676
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesWuhan, Zhengzhou
- Not yet recruitingNeoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06814158
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingQL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06822985
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingA Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT06823050
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- Not yet recruitingPredicting Gastric Neoplasia in Patients with High-risk Endoscopic Features
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT06853509
Age 45 years to Not stated (registered criteria)
Led by Huadong Hospital, Fudan UniversityShanghai
- Not yet recruitingEffectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06861348
Age 14 years to 65 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingTotal Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Registry
- NCT06861777
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingActive Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT06861894
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingFruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Registry
- NCT06871527
Age 18 years to 75 years (registered criteria)
Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- Not yet recruitingFruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06888037
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingPrognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
- Phase
- Not given
- Started
- 2025-04
- Registry
- NCT06889402
Age 18 years to 85 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingA Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Started
- 2025-04
- Registry
- NCT06895512
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingIcaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Registry
- NCT06896396
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingPD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06900218
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingIcariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06900478
Age 18 years to 80 years (registered criteria)
Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- Not yet recruitingJY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia
- Phase
- N/A
- Started
- 2025-03
- Registry
- NCT06902025
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingToripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06903871
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingUCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
- Phase
- Early phase 1
- Started
- 2025-04
- Registry
- NCT06933563
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingA Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06935175
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingRelationship Between FGF19 Overexpression and Disease Prognosis
- Phase
- Not given
- Started
- 2025-05
- Registry
- NCT06938451
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingA Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06944496
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingDose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis
- Phase
- Phase 2/Phase 3
- Started
- 2025-06
- Registry
- NCT06951971
Age 1 year to 70 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingA Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06957977
Age 18 years to Not stated (registered criteria)
Led by Huashan HospitalShanghai
- Not yet recruitingComparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06963866
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou
- Not yet recruitingTreatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study
- Phase
- N/A
- Started
- 2025-05
- Registry
- NCT06964971
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Zhejiang Chinese Medical UniversityHangzhou
- Not yet recruitingThe Application Value of Spectral CT in the Accurate Staging of Gastric Cancer
- Phase
- N/A
- Started
- 2025-06
- Registry
- NCT06977386
Age 18 years to 80 years (registered criteria)
Led by Yunnan Cancer HospitalKunming
- Not yet recruitingUCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT06978738
Age 18 years to Not stated (registered criteria)
Led by Changzhou No.2 People's HospitalChangzhou
- Not yet recruitingNode-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC)
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06980389
Age 18 years to 75 years (registered criteria)
Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- Not yet recruitingComparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
- Phase
- N/A
- Started
- 2025-06
- Registry
- NCT07010588
Age 18 years to 75 years (registered criteria)
Led by Peking University People's Hospital; 8 listed hospitals as study sitesBeijing, Changchun, Chongqing, Harbin, Jinan, Qingdao, Wuhan, Xi'an
- Not yet recruitingTherapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
- Phase
- N/A
- Started
- 2025-06
- Registry
- NCT07014254
Age 18 years to 80 years (registered criteria)
Led by Xijing HospitalXi'an
- Not yet recruitingNeoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-10
- Registry
- NCT07018063
Age 16 years to 45 years (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingPD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer
- Phase
- Phase 1
- Started
- 2025-06
- Registry
- NCT07031011
Age 18 years to 75 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- Not yet recruitingDefinitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07034118
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- Not yet recruitingPhase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
- Phase
- N/A
- Started
- 2025-07
- Registry
- NCT07034755
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou
- Not yet recruitingA Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
- Phase
- Phase 1
- Started
- 2025-06
- Registry
- NCT07036185
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT07043218
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalShanghai
- Not yet recruitingRisk-adapted Therapeutic Strategy in +1q NDMM
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07045168
Age not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- Not yet recruitingHAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07045558
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingOmega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07050524
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingA Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2025-07
- Registry
- NCT07062484
Age 18 years to Not stated (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- Not yet recruitingTauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07064668
Age 18 years to 80 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingPerioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Registry
- NCT07068516
Age 18 years to 80 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingShrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity
- Phase
- Phase 3
- Started
- 2025-08
- Registry
- NCT07072000
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Wuzhou, Zhanjiang
- Not yet recruitingEfficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07078721
Age 18 years to 50 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingEx Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia
- Phase
- N/A
- Started
- 2025-09
- Registry
- NCT07087847
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingComparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT07088744
Age 18 years to 80 years (registered criteria)
Led by Changhai Hospital; 1 listed hospital as study siteChengdu, Shanghai
- Not yet recruitingA Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Registry
- NCT07090954
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Xi'an
- Not yet recruitingAcupuncture Combined With Chemotherapy for Gastric Cancer After Surgery
- Phase
- N/A
- Started
- 2025-08
- Registry
- NCT07098949
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou
- Not yet recruiting29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07100236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou
- Not yet recruitingA Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07112833
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingRN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07113496
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingRN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07114432
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingA Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07131501
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingThe Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- N/A
- Started
- 2025-09
- Registry
- NCT07139587
Age 18 years to 75 years (registered criteria)
Led by Hebei General HospitalShijiazhuang
- Not yet recruitingEndostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
- Phase
- Phase 1
- Started
- 2025-09
- Registry
- NCT07154108
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingA Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07156617
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHaikou, Nanchang, Zhengzhou
- Not yet recruitingGecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07157306
Age 18 years to 80 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingClinical Application of PET Imaging Targeting GPA33 in Malignant Tumors
- Phase
- N/A
- Started
- 2025-10
- Registry
- NCT07172503
Age 18 years to 70 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingThe Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib:A Prospective, Single-arm, Multicenter, Observational Study
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07180459
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHaikou
- Not yet recruitingStudy of CM336 in Relapsed or Refractory Multiple Myeloma Patients
- Phase
- Phase 3
- Started
- 2025-09
- Registry
- NCT07181239
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingFamily-Supervised Prehabilitation to Reduce Postoperative Complications After Neoadjuvant Chemotherapy in Gastric Cancer
- Phase
- N/A
- Started
- 2025-09
- Registry
- NCT07183358
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- Not yet recruitingEDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Registry
- NCT07187284
Age 18 years to 75 years (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- Not yet recruitingAdebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07192848
Age 18 years to Not stated (registered criteria)
Led by Cancer Hospital CAMS – ShenzhenShenzhen
- Not yet recruitingEFG vs IVIG in TAMG
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07231523
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingA Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07233850
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Not yet recruitingA Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
- Phase
- Phase 1
- Started
- 2025-11
- Registry
- NCT07234045
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingA Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07239986
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHefei, Shanghai
- Not yet recruitingFeasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07257380
Age 18 years to 79 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingProspective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
- Phase
- Not given
- Started
- 2025-12
- Registry
- NCT07266051
Age 18 years to Not stated (registered criteria)
Led by Xiamen Hospital; 3 listed hospitals as study sitesShanghai, Xiamen
- Not yet recruitingNovel Humanized Ferritin-based NIR Fluorescent Molecular Probe for Identifying Tumor Margins in Gastric Tissue
- Phase
- Not given
- Started
- 2025-12
- Registry
- NCT07276854
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- Not yet recruitingAn Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease
- Phase
- Early phase 1
- Started
- 2025-12
- Registry
- NCT07298590
Age 18 years to 70 years (registered criteria)
Led by Changhai HospitalShanghai
- Not yet recruitingBEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07301138
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingA Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07304258
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
- Phase
- Not given
- Started
- 2025-12
- Registry
- NCT07320326
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingTACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07350070
Age 18 years to 75 years (registered criteria)
Led by Tongji Hospital; 4 listed hospitals as study sitesFuzhou, Jinan, Nanning, Qingdao, Wuhan
- Not yet recruitingPredictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
- Phase
- N/A
- Started
- 2025-12
- Registry
- NCT07350824
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingSintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07352007
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- Not yet recruitingEffect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
- Phase
- Phase 4
- Started
- 2024-07
- Registry
- NCT05498766
Age 18 years to 75 years (registered criteria)
Led by Union Hospital; 1 listed hospital as study siteQingdao, Wuhan
- Not yet recruitingRAE Versus MIE in Patients With Esophageal Cancer After Neoadjuvant Therapy
- Phase
- N/A
- Started
- 2024-01
- Registry
- NCT06012214
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingPostoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06089369
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingInduction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC
- Phase
- Phase 3
- Started
- 2024-01
- Registry
- NCT06095167
Age 18 years to 70 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- Not yet recruitingA Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT06196775
Age 18 years to 75 years (registered criteria)
Led by Harbin Medical University HospitalHarbin
- Not yet recruitingEfficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction,a Phase II Clinical Study
- Phase
- Phase 2
- Started
- 2024-02
- Registry
- NCT06241469
Age 18 years to 80 years (registered criteria)
Led by Third Affiliated Hospital of Soochow UniversityChangzhou
- Not yet recruitingTo Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2024-03
- Registry
- NCT06298266
Age 18 years to 75 years (registered criteria)
Led by Guangdong Second Provincial General HospitalGuangzhou
- Not yet recruitingNeoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06310473
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- Not yet recruitingValue of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
- Phase
- Not given
- Started
- 2024-04
- Registry
- NCT06317896
Age 18 years to 75 years (registered criteria)
Led by Zhujiang Hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingA Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06369935
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingKSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial
- Phase
- Early phase 1
- Started
- 2024-05
- Registry
- NCT06370026
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingTislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06374901
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingEvaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer
- Phase
- N/A
- Started
- 2024-05
- Registry
- NCT06421220
Age 18 years to 75 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- Not yet recruitingCompare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06449846
Age 18 years to 75 years (registered criteria)
Led by Zhujiang Hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingConversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06454435
Age 18 years to 70 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingLCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- N/A
- Started
- 2024-07
- Registry
- NCT06472479
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province Hospital; 2 listed hospitals as study sitesHefei, Nanjing, Zhengzhou
- Not yet recruitingA Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06487702
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingRC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06492317
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingProspective Observational Cohort Study
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06493448
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingA Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant Tumors
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06496919
Age 18 years to 80 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- Not yet recruitingClinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer
- Phase
- Phase 4
- Started
- 2024-07
- Registry
- NCT06499610
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an
- Not yet recruitingA Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-08
- Registry
- NCT06500507
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingSurufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06531291
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingHema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
- Phase
- Early phase 1
- Started
- 2024-09
- Registry
- NCT06559644
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingAllogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06594211
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingA PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06614751
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- Not yet recruitingClinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06641024
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingCAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Registry
- NCT06641453
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingSHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06666166
Age 18 years to 75 years (registered criteria)
Led by First Hospital of China Medical UniversityShenyang
- Not yet recruitingNeoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06680115
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Guangxi Medical UniversityNanning
- Not yet recruitingCadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06681285
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingA Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06724263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingComparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06748508
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingSintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06752382
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingSafety and Efficacy Study of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06756841
Age 20 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingAdjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study
- Phase
- N/A
- Started
- 2023-03
- Registry
- NCT05602974
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingSBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
- Phase
- Phase 3
- Started
- 2023-03
- Registry
- NCT05718232
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- Not yet recruitingA Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
- Phase
- Phase 3
- Started
- 2023-04
- Registry
- NCT05780294
Age 18 years to 60 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingLaparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer
- Phase
- N/A
- Started
- 2023-06
- Registry
- NCT05890339
Age 20 years to 80 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingPerioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2023-07
- Registry
- NCT05970627
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Ningbo
- Not yet recruitingA Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
- Phase
- Phase 2/Phase 3
- Started
- 2023-09
- Registry
- NCT05976568
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- Not yet recruitingEfficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
- Phase
- N/A
- Started
- 2023-08
- Registry
- NCT05988177
Age 18 years to Not stated (registered criteria)
Led by Beijing Friendship HospitalBeijing
- Not yet recruitingAdjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
- Phase
- Phase 2
- Started
- 2023-09
- Registry
- NCT06041490
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingSegmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
- Phase
- Not given
- Started
- 2023-12
- Registry
- NCT06131489
Age 18 years to Not stated (registered criteria)
Led by Beijing Friendship HospitalBeijing
- Not yet recruitingA Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
- Phase
- Phase 1/Phase 2
- Started
- 2023-12
- Registry
- NCT06136988
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingA Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2023-12
- Registry
- NCT06152978
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingNeoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
- Phase
- Phase 2
- Started
- 2023-12
- Registry
- NCT06178211
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingUmbrella Biomarker-Guided Therapy in NPC
- Phase
- Phase 2
- Started
- 2022-06
- Registry
- NCT04605562
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
- Phase
- Phase 1
- Started
- 2022-04
- Registry
- NCT05181501
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangzhou, Hefei, Nanjing
- Not yet recruitingthe Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric Cancer
- Phase
- N/A
- Started
- 2022-02
- Registry
- NCT05235932
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Not yet recruitingSintilimab Plus NCT or NCRT Versus NCRT for ESCC
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05244798
Age 18 years to 75 years (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- Not yet recruitingThe Safe Study of Routine Closure of Mesenteric Defects Versus Non-closure After Radical Gastrectomy
- Phase
- N/A
- Started
- 2022-04
- Registry
- NCT05356156
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingPembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2022-12
- Registry
- NCT05386056
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingTwo-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
- Phase
- N/A
- Started
- 2022-07
- Registry
- NCT05420480
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingClinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
- Phase
- Phase 2
- Started
- 2022-09
- Registry
- NCT05524974
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Not yet recruitingClinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05610332
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Not yet recruitingA Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy
- Phase
- N/A
- Started
- 2022-11
- Registry
- NCT05622474
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingEarly Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
- Phase
- Phase 3
- Started
- 2021-03
- Registry
- NCT04215510
Age 18 years to 70 years (registered criteria)
Led by Eye & ENT Hospital of Fudan University; 3 listed hospitals as study sitesFuzhou, Nanchang, Shanghai
- Not yet recruitingDragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
- Phase
- Phase 3
- Started
- 2021-09
- Registry
- NCT04384601
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingA Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2021-01
- Registry
- NCT04670055
Age 30 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingTotal Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric Cancer
- Phase
- N/A
- Started
- 2021-03
- Registry
- NCT04795063
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Not yet recruitingAn Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
- Phase
- Phase 2/Phase 3
- Started
- 2021-07
- Registry
- NCT04890522
Age 18 years to 60 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy
- Phase
- Early phase 1
- Started
- 2020-12
- Registry
- NCT04541368
Age 30 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingCD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
- Phase
- Early phase 1
- Started
- 2020-11
- Registry
- NCT04609241
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingEndoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer
- Phase
- N/A
- Started
- 2019-03
- Registry
- NCT03857737
Age not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- Enrolling by invitationEarly Postoperative Intervention in Gastric Cancer Patients
- Phase
- N/A
- Started
- 2026-02
- Registry
- NCT07444099
Age 18 years to 80 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- Enrolling by invitationAnemia on Sublingual Microcirculation in GDFT
- Phase
- Not given
- Started
- 2026-05
- Registry
- NCT07583927
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Enrolling by invitationNon-surgical Management After NIT for dMMR/MSI-H GC
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07646574
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- Enrolling by invitationLong-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
- Phase
- Not given
- Started
- 2026-11
- Registry
- NCT07833046
Age not stated (registered criteria)
Led by Renji HospitalShanghai
- Enrolling by invitationPrognostic Value of TIL in Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT06763640
Age 18 years to 70 years (registered criteria)
Led by Jiangxi Cancer HospitalNanchang
- Enrolling by invitationJS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT06882876
Age 18 years to 75 years (registered criteria)
Led by Xiangya HospitalChangsha
- Enrolling by invitationRadiomics-Based AI Model for Predicting Para-Aortic Lymph Node Metastasis in Gastric Cancer Patients
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT06947096
Age 18 years to 80 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Enrolling by invitationAI-Based Prediction of Lymph Node Metastasis in Gastric Cancer Using Preoperative Multimodal Data
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT06957678
Age 18 years to 80 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Enrolling by invitationDiagnostic Accuracy of Endocytoscopy for Superficial Esophageal Neoplasia
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT06984055
Age 18 years to 85 years (registered criteria)
Led by Changhai HospitalShanghai
- Enrolling by invitationPET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT07023848
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Jiangnan UniversityWuxi
- Enrolling by invitationThe Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT07023861
Age 15 years to 75 years (registered criteria)
Led by Affiliated Hospital of Jiangnan UniversityWuxi
- Enrolling by invitationExplainable Machine Learning for Predicting Early Gastric Cancer
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07047937
Age not stated (registered criteria)
Led by Wenzhou Central HospitalWenzhou
- Enrolling by invitationAn Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric Adenocarcinoma
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07274579
Age 18 years to Not stated (registered criteria)
Led by Nanfang Hospital; 1 listed hospital as study siteGuangzhou, Jinan
- Enrolling by invitationSurvival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy
- Phase
- Not given
- Started
- 2025-12
- Registry
- NCT07290764
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial HospitalFuzhou
- Enrolling by invitationNimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07312578
Age 18 years to 70 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Enrolling by invitationClinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Phase
- Early phase 1
- Started
- 2025-05
- Registry
- NCT07356466
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Enrolling by invitationBased on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy
- Phase
- Early phase 1
- Started
- 2025-12
- Registry
- NCT07371247
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Enrolling by invitationSafety and Efficacy of Leucine-Restricted Diet in Gastric Cancer
- Phase
- Phase 1
- Started
- 2025-10
- Registry
- NCT07488312
Age 18 years to 70 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- Enrolling by invitationLaparoscopic Staging for Stage III Gastric Cancer
- Phase
- N/A
- Started
- 2025-02
- Registry
- NCT07533825
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Enrolling by invitationInfiltration Pattern of Locally Advanced ESCC
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07567716
Age not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Enrolling by invitationA Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06647264
Age 18 years to 80 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- Enrolling by invitationIMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06688175
Age 65 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- Enrolling by invitationEvaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Registry
- NCT06690216
Age 18 years to Not stated (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- Enrolling by invitationObservational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06712017
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- Enrolling by invitationEfficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06715501
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Ningbo UniversityNingbo
- Enrolling by invitationA Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06863831
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Enrolling by invitationImmunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy
- Phase
- Phase 3
- Started
- 2024-08
- Registry
- NCT07016737
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Cancer HospitalNanjing
- Enrolling by invitationEGPSS for Weight Management in an in Vivo Human Model
- Phase
- N/A
- Started
- 2024-07
- Registry
- NCT07186959
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Enrolling by invitationFufang Tongluo Decoction as an Adjunct to Aspirin and Atorvastatin for Ischemic Moyamoya Disease
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT07875335
Age 18 years to 60 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Enrolling by invitationClinical Safety and Efficacy Evaluation of the Blood-cooling and Stasis-removing Formula as an Adjunct to Atorvastatin in the Treatment of Hemorrhagic Moyamoya Disease.
- Phase
- Early phase 1
- Started
- 2024-12
- Registry
- NCT07894640
Age 18 years to 60 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Enrolling by invitationClinical Evaluation of the Safety and Efficacy of "Buyan Huan Wu Tang" Combined With Atorvastatin in the Treatment of Atypical Pneumonia
- Phase
- Early phase 1
- Started
- 2024-12
- Registry
- NCT07906652
Age 18 years to 60 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Enrolling by invitationA Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2023-11
- Registry
- NCT06160557
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial HospitalFuzhou
- Enrolling by invitationNormal Chinese Lifespan Brain Charts Initiative (NCLBCI)
- Phase
- Not given
- Started
- 2023-12
- Registry
- NCT06643858
Age 6 years to 90 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- Enrolling by invitationScreening of Small Non-coding RNAs as an Auxiliary Diagnostic Biomarker for Gastric Cancer
- Phase
- Not given
- Started
- 2023-12
- Registry
- NCT06776835
Age 18 years to 85 years (registered criteria)
Led by Affiliated Hospital of Nantong UniversityNantong
- Enrolling by invitationProlonged Extubation in Gastric Cancer With OSA
- Phase
- Not given
- Started
- 2023-01
- Registry
- NCT07362706
Age 18 years to 85 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- Enrolling by invitationCarrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- N/A
- Started
- 2022-07
- Registry
- NCT06048926
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Enrolling by invitationNeoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2022-06
- Registry
- NCT06303583
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Enrolling by invitationPhase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA
- Phase
- Phase 1/Phase 2
- Started
- 2022-08
- Registry
- NCT07299123
Age 6 years to 60 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Enrolling by invitationA Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
- Phase
- Phase 2
- Started
- 2021-12
- Registry
- NCT05441475
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Enrolling by invitationThe Efficacy of Sequential RT After Triple Therapy for uHCC
- Phase
- Not given
- Started
- 2020-11
- Registry
- NCT07052448
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial HospitalFuzhou
- Enrolling by invitationAI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities
- Phase
- Not given
- Started
- 2018-08
- Registry
- NCT07410403
Age not stated (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- Enrolling by invitationAutologous Stem Cell Transplantation for Patients With AL Amyloidosis
- Phase
- Not given
- Started
- 2010-07
- Registry
- NCT04210791
Age 18 years to 75 years (registered criteria)
Led by Jinling HospitalNanjing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.